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The immune system consists of two major types of lymphoid tissues. Primary lymphoid 
organs like the thymus, which is responsible for generation of T cells from precursors, and 
secondary lymphoid tissues such as spleen and lymph nodes, which represent sites of immune 
induction. Naïve T cell circulate between the different secondary lymphoid compartments, 
examining antigen presenting cells (APC) for the presence of their cognate ligand presented 
by the Major Histocompatibility Complex (MHC). To survey the entire body, T cells rely on 
the trafficking of antigen, associated with APCs, from peripheral tissues via the lymphatics or 
blood to the secondary lymphoid organs. The APC activate the naïve T cells, causing their 
expansion and differentiation into effector cells. Once they leave the lymph node, effector T 
cells are able to enter peripheral tissues, specifically targeting sites of inflammation where 
they perform their specific immune fuction. 
T lymphocytes can be divided into two subpopulations on the basis of their expression of the 
cell-surface markers CD4 and CD8. The CD4+ subset is primarily responsible for providing 
help to other immune cells through direct cell-cell interactions or the secretion of cytokines. 
Priming of CD8+ T cells leads to their development into mature cytotoxic T lymphocytes 
(CTLs), which are best known for their capacity to kill virus-infected cells. 
T cells use their T-cell receptor (TCR) to recognize peptide antigens presented by molecules 
encoded by the major histocompatibility complex (MCH). CD4+ T cells recognize peptides 
presented by MHC class II molecules. These peptides are derived from exogenous antigens 
that enter the cell by the endocytic route. CD8+ T cells are restricted to MHC class I 
molecules, which present endogenously derived antigens, usually synthesized within the cell 
presenting the antigen. The targeting of CD8+ T cells to endogenously synthesized antigens is 
important as it ensures that virus-specific CTLs only kill cells that are directly infected with 
virus.  
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Some APC are able to present also exogenous antigen in MHC class I, a process called cross-
presentation. This process induces optimal T cell induction against peripheral antigens. It 
provides the immune system with a mechanism by which it can detect and respond to 
antigens in non-lymphoid tissue. The mechanisms underlying cross-presentation are not yet 
fully understood. Some groups report the existence of a process whereby phagosomes fuse 
with endoplasmic reticulum (ER)-derived vesicles1,2. The resulting phagosome-ER hybrid 
compartment contains newly synthesized MHC class I molecules together with the 
components required for MHC class I peptide loading, such as the transporter associated with 
antigen presentation (TAP), tapasin, calreticulin, and ERp573. Phagocytosed antigens might 
then be transported to the cytosol adjacent to the phagosome by an as yet undefined 
mechanism. It is thought that the exogenous antigens are then degraded by closely associated 
proteasomes, and the resulting peptides are transported back into the phagosome via the TAP 
complex for loading onto class I molecules. 
 
Antigen Presenting Cells 
The major cell type known for its capacity to cross-present antigens is the dendritic cell 
(DC)4,5,6,7,8. However, also several other cell types have also been reported to cross-present, 
including B cells, endothelial cells and particularly macrophages9,10,11,12,13,14,15,16. 
Dendritic cells have no absolute defining characteristics, but they can be generally 
characterized as leukocytes that express the integrin CD11c and in their mature from express 
high levels of MHC class II, co-stimulatory molecules CD80 and CD86, are veiled or 
dendritic in appearance, and are able to initiate primary immune responses. Mouse DC can be 
divided into 6 subpopulations (table 1)17. DC in lymphoid tissue can be divided into CD8- and 
CD8+ subpopulations, from which the CD8- DC can be further subdivided in CD4-CD8- and 
CD4+CD8- subsets. 
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Table 1 Organ distribution of mouse dendritic cell subpopulations
DC subpopulation thymus spleen lymph node peyer's patch skin liver
CD8- DC * + + + - +
CD8+ DC + + + + - +
CD8int DC - - + - - -
langerhans cells - - - - + -
dermal DC - - - - + -
B220+ DC + + + + - nd
*CD8- DC can be detected in the thymus, although they constitue a minute proportion in thymic DC.
+, present; -, absent; CD8int, intermediate level of expression of CD8; DC, dendritic cell; nd, not determined
adapted from C. Ardavin, Nature Reviews, 2003  
 
Immune complexes 
Several types of antigens have been reported to be cross-presented. These include soluble 
proteins8,18, immune complexes6,19 (IC), intracellular bacteria20, parasites21, and cellular 
antigens22,23,24,25,26,27,28,14,29. Examination of the efficiency of cross-presentation of soluble 
versus cell-associated ovalbumin (OVA) in vivo shows that after i.v. administration, cellular 
OVA is cross-presented with 50x103-fold more efficiency than soluble OVA30. This finding 
suggests that access of soluble proteins to this pathway is poor, but it is also possible that 
soluble OVA is quickly eliminated by serum proteases or sequestered from the medium by 
active uptake or adherence to bystander cells.  
In contrast to soluble antigen, antigen-immunoglobulin (Ig)G complexes (IC) appear to be 
efficiently cross-presented19, and they are possibly important in the induction of rapid 
secondary responses to intracellular pathogens for which antibody responses have been 
previously generated. 
IC are also found at sites of inflammation in several autoimmune diseases and it has been 
postulated that the pathogenesis of autoimmune diseases involves the formation of IgG-
containing IC inducing harmful inflammatory responses, commonly referred to as type III 
hypersensitivity reaction. Circulating Abs, complement deposition, or vasculitis indicating 
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IC-mediated disease are detectable in conditions such as rheumatoid arthritis, systemic lupus 
erythematosus, cryoglobulinemia, or hypersensitivity pneumonitis31,32,33,34,35. 
 
FcReceptors 
Part of the inflammatory response is attributed to the binding of IC to Fc receptors for IgG 
(FcγR) on leukocytes. FcR bind the Fc part of the constant region of Ig. By cross-linking 
FcγRs, a variety of cellular responses are triggered including phagocytosis, antibody-
dependent cellular cytotoxicity, release of inflammatory mediators, IC clearance, and 
regulation of antibody production. In this way, FcγRs form a molecular link between the 
humoral and cellular branches of the immune system36. 
In mice four classes of leukocyte FcγR can be recognized: FcγRI, FcγRII, FcγRIII and 
FcγRIV, which are widely distributed on different cell types including B and T lymphocytes, 
dendritic cells, neutrophils, natural killer cells and monocytes/macrophages37,38,39,40. 
Functionally, FcγR can be divided in two groups: activating FcγR (FcγRI, FcγRIII and 
FcγRIV) and an inhibiting FcγR (FcγRII). The activating receptors are associated with a 
dimer of γ chains (figure 1), which is required for intracellular signalling through the receptor 
and for stable surface expression. The γ chain contains a single cytoplasmic immunoreceptor 
tyrosine-based activation motifs (ITAM), which are conserved among a number of activating 
receptors, like the B cell receptor (BCR) and the T cell receptor (TCR). Furthermore, the γ 
chain is also associated to other receptors as for example the high-affinity receptor for IgE 
(FcεR), the receptor for IgA (FcαR) and other surface molecules like PIR-A. The inhibitory 
receptor, in contrast, contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in 
their intracellular region. 



























Figure 1: schematic representation of murine FcγR. 
The murine activating FcγR, FcγRI, FcγRIII and FcγRIV, are multi-subunit receptor complexes, containing a 
ligand-binding α chain and a ITAM-containing signal transducing subunit. The inhibiting FcγRII is a single-
chain receptor with a ITIM-motif. 
 
 
One of the crucial features of FcγR is their ability to enhance antigen presentation of IgG-
containing IC by antigen-presenting cells (APC), such as dendritic cells, which leads to the 
activation of antigen-specific T cells (figure 2)41,42. FcγR-mediated antigen uptake can 
enhance antigen presentation by DC to activate CD4+ and CD8+ T cells both in vitro43,19 and 
in vivo44; this implies that FcγR have a pivotal role in augmenting humoral and cellular 
immune responses by increasing antigen-presentation. In recent studies, targeting antigen to 
FcγR on bone-marrow-derived DC by complexing the antigen with anti-antigen IgG 
successfully elicited humoral responses that consisted of antigen-specific IgG production in 
vivo. In contrast to DC from wild-type mice, antigen-pulsed DC from FcγR-deficient mice 
were unable to activate antigen-specific cytotoxic T lymphocytes in vivo. These findings 
















Figure 2: antigen uptake via FcγR on antigen-presenting cells. 
Antigen-immunoglobulin complexes are taken up via the FcγR, processed into peptides and presented on MHC 
class I or II. 
 
 
The complement system 
The complement system plays an important role in the immune system, providing a highly 
effective means for the destruction of invading microorganisms and for immune complex 
elimination. It is a major component of innate immunity and is also involved in the initiation 
of an adaptive immune response46,47. The activation cascade of complement is controlled by a 
large number of soluble and membrane-bound regulatory proteins. Three pathways of 
complement activation have been described, the classical pathway, the alternative pathway 
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and the lectin (i.e. mannan-binding lectin and ficolins) pathway (figure 3). Each pathway has 
its own activation and recognition mechanism, resulting in the formation of C3-convertases 
that cleave the central complement component C3 into the fragments C3a and C3b. Binding 
of C3b enables a better clearance of pathogens and immune complexes as well as the 
generation of the lytic membrane attack complex, C5b-9. 
 
Immune complexes are able to activate the complement system via de classical pathway, by 
binding of the recognition molecule C1q. C1q contains a collagen-like tail region (CLR) to 
which the serine proteases C1r and C1s are bound, connected to a globular head region that is 
responsible for ligand binding. Upon binding to its ligand, C1q changes conformation, which 
leads to the activation of its associated serine proteases C1r and C1s. C1s cleaves C4 and C2 
leading to the formation of the C4b2a complex which is the classical pathway convertase. 
Both the classical pathway and lectin pathway C3 convertase C4b2a and the alternative 
pathway C3 convertase C3bBb form C5 convertases by the inclusion of a C3b molecule to 
the C3 convertase. From the C5 convertase level all pathways follow a common terminal 
pathway, potentially up to the formation of the membrane attack complex. Activation of C5  
and binding of complement components C6, C7, C8 and multiple C9 molecules, finally 
generate the membrane attack complex C5b-9. This membrane attack complex forms a pore 
in cell membranes, leading to loss of permeability control and potentially cell lysis. Cleavage 
of C5 also generates C5a, which is a potent chemotactic factor. 
 





























































Figure 3: schematic overview of the three pathways of complement activation and several functions of the 
complement factors. 
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By interacting with a variety of cellular receptors, the complement system can influence 
cellular effector functions (table 2)48. Chemotactic factors like C3a and C5a interact with the 
C3a and C5a receptors, respectively, including cellular activation and chemotaxis. During 
complement activation, targets become opsonized by C4b, C3b and their degradation 
products. This may lead to target recognition via complement receptors (CR1, CR2, CR3 and 
CR4) which are present on various cells of the immune system, leading to phagocytosis and 
induction of acquired immunity. Binding of complement-opsonized immune complexes to 




Table 2 Complement receptors
endothelium, B cells, myeloid cells, etc.C1q, MBLCalreticulin
endothelium, monocytes, platelets, DCC1q?, MBL?CD93C1qRP
endothelium, B cells, T cells, plateletsC1qgC1q binding protein
neutrophils, DC, etc.C5a, C3a, C4agpr77C5L2
neutrophils, mast cells, monocytes, 
macrophages, platelets, DC, epithelial cells, 
endothelium, etc.
C5aCD88C5aR
neutrophils, mast cells, monocytes, 
macrophages, platelets, DC, epithelial cells, 
etc.
C3a, C4aC3aR
myeloid cells, DC, B cellsiC3bCD11c/CD18CR4
phagocytes, NK, DCiC3bCD11b/CD18CR3
B cells, FDCC3d, iC3bCD21CR2
leukocytes, erythrocytes, monocytes, FDC, 
podocytes, B cells, T cells




aThe indicated expression pattern is not complete. DC: dendritic cells, FDC: follicular dendritic cells, NK: natural killer 
cells. Adapted from A. Roos et al, Encyclopedia of the human genome, 2003.
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C1q 
C1q has been shown to have a number of functions, not directly related to complement, that 
could be mediated by recently identified binding proteins acting as cell-surface receptors or 
soluble modulators of C1q-mediated functions49. To date, four types of putative C1q binding 
cell-surface expressed proteins/receptors have been described. These include cC1q-R/CR, or 
calreticulin (CR), also known as the collectin receptor; gC1q-R/p33; C1q-Rp (CD93); and 
CR1 (CD35), the receptor for C3b50,51,52,53,54,55,56. 
 
Autoimmunity 
Under normal conditions the contribution of the complement system is beneficial to the host. 
However when inappropriately activated it may also contribute to damage. Deficiency of an 
early component of the classical pathway, C1q, C1r/C1s, C4, or C2, regularly produces 
autoimmunity in man. It has long been suggested that disruption of this pathway would lead 
to the inappropriate handling of immune complexes. In several autoimmune diseases 
complement components can be the target of an autoantibody response. Inappropriate 
activation of complement has been implicated in a large number of diseases57, such as 
cardiovascular58, neurological59 and several renal diseases60. 
 
Complement factor 5 in rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and is a major cause of 
disability. Early theories on the pathogenesis of RA focused on autoantibodies and immune 
complexes. T cell-mediated antigen-specific responses, T cell-independent cytokine 
networks, and aggressive tumor-like behaviour of rheumatoid synovium have also been 
implicated. More recently, the contribution of autoantibodies has returned to the forefront. 
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The recent unexpected discovery of a spontaneous arthritis model in mice that produce 
antibodies directed against ubiquitous antigen, glucose-6-phosphoisomerase (GPI), 
contributed to resurgent interest in autoantibodies and immune complexes61. The murine 
arthritis can be transferred using serum from affected mice. Elegant molecular studies using 
knock-out mice demonstrate an absolute requirement for FcγR and components of the 
alternative complement cascade as well as complement proteins C3 and C562. 
The complement network was initially implicated in human RA, indirectly, by the co-
localization of C3 fragments with immune complexes in joint tissue63, and by the 
demonstration that complement activity, as well as early-acting components (C2, C4), is 
routinely depressed in synovial fluid of patients64. More recently, more direct evidence of 
complement activation in arthritic joints has been reported65. As mice deficient for C5 are 
resistent to serum induced arthritis66 and anti-C5 monoclonal antibody treatment prevents 
arthritis in mice62, it is tempting to speculate that the complement system also plays an 
important role in human. 
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Scope of the thesis 
 
The aim of this thesis is to investigate the role of the different FcγR in IC-medicated antigen-
presentation in vivo as well as to study the role of complement factors in (auto)immune 
responses. 
DC are the major APC of the immune system that are involved in initiation of CD4+ and 
CD8+ T cell responses, as DC display many receptors involved in antigen uptake, including 
several types of FcγR. However, other APC, like B cells and macrophages also express FcγR 
and MHC class II molecules. In chapter 2 of this thesis we show the contribution of these 
three different APC, in mice, in the Ag-specific MHC class II restricted activation of CD4+ T 
cells by systemically administrated Ag-complexed IC. 
In chapter 3 we analyzed the contribution of FcγR and the complement system in the 
presentation of immune-complexed Ag to CD8+ T cells after intravenous administration of 
IC. Here C1q appeared to play an important role. 
The study described in chapter 4 is aiming at identifying the role and importance of 
individual Fcγ-receptors in the initiation and regulation of CD8+ T cell responses after 
subcutaneous injection of IC. Following this route of application, Fcγ-receptors appeared to 
be redundant in the uptake and presentation of immune-complexed Ag. 
As mice deficient for C5 are unsusceptible to serum induced arthritis and anti-C5 monoclonal 
antibody treatment prevents arthritis in mice, the question is addressed whether human RA is 
also associated with C5. The results of this study are shown in chapter 5. 
Finally, in chapter 6 the results of this thesis are summarized and discussed. 
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Dendritic cells, but not macrophages or B cells, activate major
histocompatibility complex class II-restricted CD4+ T cells upon
immune-complex uptake in vivo
Introduction
CD4+ T cells can control many activities of the immune
system. In order to exert their action, the CD4+ T cells
need to recognize their specific antigen in the context of
major histocompatibility complex (MHC) class II mole-
cules. In contrast to MHC class I molecules, MHC class
II molecules have a more restricted distribution pattern,
and they are predominantly expressed, under normal
conditions, by professional antigen-presenting cells (APC),
like B cells, macrophages and dendritic cells. These profes-
sional APC also express a variety of receptors that are
involved in the uptake of potentially antigenic materials.
For example, it has been shown that DC and macrophages
can capture antigens through the uptake of, for example,
apoptotic cells, antigen-heat shock protein-complexes and
antigen–immunoglobulin (Ig)G complexes (IC).1 For the
uptake of these antigens, the APC display several receptors
like mannose-receptors, CD91, CD36, complement recep-
tors, and FccR. Although these receptors are crucial for the
clearance of pathogens or apoptotic cells, they are at the
same time also involved in the more efficient presentation
of the exogenously acquired antigen to the cellular arm of
the immune system.2,3 For example, several in vitro studies
have shown that APC present IgG-complexed antigen
much more efficiently to MHC class I-restricted CD8+ T
cells than soluble antigen.4,5 This efficient cross-presenta-
tion is dependent on the expression of FccR, and is
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Summary
Professional antigen-presenting cells (APC) are able to process and present
exogenous antigen leading to the activation of T cells. Antigen–immuno-
globulin (Ig)G complexes (IC) are much more efficiently processed and
presented than soluble antigen. Dendritic cells (DC) are known for their
ability to take up and process immune complex (IC) via FccR, and they
have been shown to play a crucial role in IC-processing onto major histo-
compatibility complex (MHC) class I as they contain a specialized cross-
presenting transport system required for MHC class I antigen-processing.
However, the MHC class II-antigen-processing pathway is distinct. There-
fore various other professional APC, like macrophages and B cells, all dis-
playing FccR, are thought to present IC-delivered antigen in MHC class
II. Nonetheless, the relative contribution of these APC in IC-facilitated
antigen-presentation for MHC class II in vivo is not known. Here we
show that, in mice, both macrophages and DC, but not B cells, efficiently
capture IC. However, only DC, but not macrophages, efficiently activate
antigen-specific MHC class II restricted CD4+ T cells. These results indi-
cate that mainly DC and not other professional APC, despite expressing
FccR and MHC class II, contribute significantly to IC-facilitated T cell
activation in vivo under steady-state conditions.
Keywords: dendritic cells; macrophages; antigen presentation/processing;
Fc receptors
Abbreviations: APC, antigen-presenting cell; DC, dendritic cell; DTR, diphtheria toxin receptor; FccR, Fc receptor for IgG; GFP,
green fluorescent protein; IC, immune complex; Ig, immunoglobulin; MACS, magnetic activated cell sorting; OVA, ovalbumin;
pMF, peritoneal macrophages.
 2006 Blackwell Publishing Ltd, Immunology, 119, 499–506
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thought to be an unique property of DC as these cells pos-
sess a specialized cross-presentation transport system for
MHC class I antigen-presentation.6–10
Although DC can efficiently present antigen from IC in
a FccR-dependent fashion in the context of both MHC
class I and class II molecules11,12 the rules governing anti-
gen-presentation for MHC class I and II molecules are
rather distinct. MHC class I-presentation of internalized
antigen taken up by DC results from antigen-shuttling
from endocytic compartments into the cytoplasm for fur-
ther processing.13 In contrast, internalized antigen can be
loaded directly onto MHC class II-molecules in MHC
class II-loading compartments for subsequent presenta-
tion to CD4+ T cells.1 Thus, unlike the requirements for
MHC class I processing and presentation, the require-
ments to allow presentation of exogenously acquired anti-
gen for MHC class II seem to be generally distributed
among professional APC.
Because MHC class II expression in conjunction with
FccR expression is not confined to DC, it has been postu-
lated that also other professional APC, like macrophages
and B cells, can equally well cross-present IgG-complexed
antigen in the context of MHC class II.5 Indeed, several
studies performed in vitro indicated that FccR can medi-
ate capture and presentation of IC by both B cells and
macrophages.14–18 However, the relative contribution of
these professional APC to IC-facilitated antigen-presenta-
tion in the context of MHC class II molecules in vivo has
not been studied in detail.
Here, we set out to determine the cross-presentation of
IC for MHC class II presentation by professional APC
(i.e. B cells, macrophages, and DC) in vivo in order to
define the relative importance of these cell types for
IC-dependent antigen-presentation in vivo. Our studies is
the first that showed that DC, and not macrophages or B
cells, despite MHC class II expression and the apparent
presence of the required MHC class II-processing machin-
ery, efficiently activate MHC class II-restricted CD4+ T
cells in vivo after injection of IC.
Materials and methods
Mice
BALB/c mice (H-2d) were obtained from Charles River
Nederland (Maastricht, the Netherlands). DO11.10
transgenic mice, which have a transgenic T-cell receptor
(TCR) specific for the ovalbumin (OVA)323)339 epitope
in the context of I-Ad, were bred in our own specific
pathogen-free animal facility. CD11c-DTR (diphtheria
toxin receptor) transgenic mice (H-2d), which carry a
transgene encoding a simian DTR-GFP (green fluores-
cent protein) fusion protein under control of the
murine CD11c promoter10,19 were also bred in our own
facility.
Antibodies
The following antibodies were purchased from Phar-
Mingen (San Diego, CA): phycoerythrin (PE)-coupled
anti-CD11c antibody (HL3), fluoroscein isothiocyanate
(FITC)-coupled anti-CD11b antibody (M1/70), FITC-
coupled goat anti-mouse (GAM) antibody, allophycocya-
nin (APC)-coupled GAM antibody and APC-coupled
anti-CD4 antibody (L3T4). The PE labelled mouse mono-
clonal antibody to the mouse DO11.10 TCR (KJI-26) was
purchased from Caltag Laboratories (Burlingame, CA).
Stainings were performed at 4 for 20 min. After washing,
the stained cells were analysed using a FACSCalibur
flow cytometer equipped with CellQuest software (Becton
Dickinson, San Jose, CA).
Generation of OVA immune complexes
Immune complexes (IC) were generated by incubating
soluble OVA (Sigma-Aldrich, Zwijndrecht, the Nether-
lands) with polyclonal OVA-specific rabbit IgG (rIg-
GaOVA) (MP Biomedicals, Aurora, OH), at a ratio of
1 lg OVA to 25 lg rIgGaOVA in phosphate-buffered
saline (PBS), for 30 min at 37. As a control, soluble
OVA was preincubated with 25 lg control rIgG (Sigma-
Aldrich). IC were then injected intravenously (i.v.) into
BALB/c or CD11c-DTR transgenic mice.
99mTc-labelling of OVA
To follow association of soluble OVA and IC to different
APC in vivo, OVA was directly labelled with 99mTc before
generation of IC. Briefly, 10 ll of an OVA solution
(10 mg/ml) was added to 4 ll of a mixture of 950 mg/l
SnCl2.2H2O and 2 g/l sodium pyrophosphate.10H2O in
PBS. Immediately thereafter, 2 ll of a solution containing
10 mg/ml of KBH4 in 01 M NaOH was added into this
mixture.20 After addition of 01 ml of 99mTc-sodium
pertechnetate solution (99mTc, approximately 200–500
MBq/ml, Technekow, Mallinckrodt Medical BV, Petten,
the Netherlands) the mixture was gently stirred at room
temperature for 1 hr. More than 95% of the OVA was
radioactively labelled with 99mTc. This labelled compound
will further be referred to as 99mTc-OVA. The radioactive
labelled OVA was further used for the generation of IC as
described above. 99mTc-labelled OVA and IC were then
i.v. injected into BALB/c mice.
Isolation of antigen-presenting cells
At several time points after i.v. injection of soluble OVA
or IC in BALB/c mice, spleen cells from these mice were
isolated and sorted for DC, macrophages and B cells.
Spleen cells were first sorted in a CD11c+ (the DC
in mice) and a CD11c– fraction, using CD11c-specific
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microbeads and the magnetic-activated cell sorting
(MACS) system (LS+ columns) (Miltenyi, CLB, Amster-
dam, the Netherlands) according to manufacturer’s
instructions. The CD11c– cells were further used to isolate
macrophages and B cells. Therefore, these cells were
stained for FITC-coupled anti-CD11b antibody (for macro-
phages) or FITC-coupled GAM antibody (for B cells) in
PBS/05% bovine serum albumin (BSA) for 15 min at 4.
Then the CD11c– CD11b+ and CD11c– GAM+ cells were
purified using anti-FITC microbeads and the MACS sys-
tem (LS+ columns). After sorting, the purified CD11c+
cells (DC), the CD11c– CD11b+ cells (macrophages), and
the CD11c– GAM+ cells (B cells) were washed and resus-
pended in Iscove’s modified Dulbecco’s medium (IMDM)
(BioWhittaker, Verviers, Belgium) supplemented with
8% heat-inactivated fetal calf serum (FCS; Bodinco,
Alkmaar, theNetherlands),100 IU/mlpenicillin/streptavidin
(BioWhittaker), 2 mM L-glutamine (Invitrogen, Breda,
the Netherlands) and 20 lM 2-mercaptoethanol (2-ME;
Merck, Hohenbrunn, Germany). This yielded cell popula-
tions that contained 922 ± 30% CD11c+ cells (DC-frac-
tion), 853 ± 26% CD11b+ cells (macrophage-fraction),
or 989 ± 03% surface Ig+ cells (B cell-fraction). Similar
techniques were applied as well in experiments analysing
the distribution of IC using 99mTc-labelled OVA or IC.
The radioactivity to each cell fraction was determined
in a dose-calibrator (VDC.101, Veenstra Instruments,
Joure, the Netherlands) at each interval/step of cell
purification.
Peritoneal macrophages were isolated from the perito-
neal cavity 24 hr following injection of 2 ml thioglycolate
medium. The peritoneal cavity was flushed with 5 ml of
ice-cold PBS. After lysis of the erythrocytes and washing
of the obtained cells, the macrophages were allowed to
adhere to tissue-coated culture plates for 1 hr. The
non-adherent cells were removed thoroughly and the
macrophages were incubated with OVA-IC for 2 hr. Sub-
sequently, the IC was washed away and the macrophages
were collected using a cell scraper and transferred to a
96-flat-bottomed plate to be used in a T-cell stimulation
assay. For these purposes, we took advantage of DO11.10-
hybridoma cells that secrete IL-2 after activation.
T-cell proliferation assay
To detect OVA presentation, the sorted DC, macrophages
and B cells were used as stimulators for OVA-specific
DO11.10 cells in a [3H]-thymidine incorporation assay.
Irradiated APC (1 · 105, 15 · 105 or 2 · 105) were incu-
bated with 05 · 105 DO11.10 cells in round bottom
plates in 150 ll IMDM. As a positive control, 001 lg/ml,
01 lg/ml or 1 lg/ml OVA323)339 peptide was added to
APC derived from untreated mice. After 72 hr, the plates
were pulsed for 18 hr with 05 lCi/well of [3H]-thymi-
dine and harvested.
Antigen-presentation in vivo
To follow T-cell proliferation in vivo, DO11.10 cells were
labelled with the intracellular fluorescent dye 5(6)-carboxy-
fluorescein diacetate succinimidyl estes (CFSE) (Molecular
Probes, Leiden, the Netherlands). Briefly, spleen and
lymph node cells were isolated from DO11.10 mice and
CD11c+ cells were removed using CD11c-specific micro-
beads and the MACS system. Cells were washed with PBS
containing 01% BSA (Sigma-Aldrich) and resuspended at
10 · 106 cells/ml in PBA/01% BSA. Next, 5 lM CFSE
was added and cells were incubated for 10 min at 37.
Then 10% FCS was added and cells were washed twice
with IMDM and resuspended in PBS/1%BSA. DO11.10
cells (3 · 106) were injected i.v. into BALB/c or CD11c-
DTR transgenic mice.
To deplete CD11c+ cells in vivo, CD11c-DTR transgenic
mice were injected intraperitoneally (i.p.) with 4 ng diph-
theria toxin (DT; Sigma)/4 g body weight in 200 ll PBS.
In these mice the DTR is inserted under the CD11c-
promoter.19 Eighteen hr after DT injection, BALB/c and
CD11c-DTR transgenic mice were i.v. injected with IC.
Three days thereafter, cells from the spleen and inguinal
lymph nodes were analysed for proliferation of the
DO11.10 cells using a FACSCalibur flow cytometer.
Results
IC are efficient in inducing CD4+ T-cell proliferation
in vivo
Professional APC are able to capture, process and present
exogenous antigen leading to activation of T cells. Several
in vitro studies showed that antigen complexed with IgG
are much more efficiently presented than soluble antigen
in a FccR-mediated fashion.4,5 To determine whether this
enhancement also occurs in vivo in the context of MHC
class II, wild type mice were injected with CFSE-labelled
OVA-specific CD4+ T cells derived from DO11.10 mice
and treated with different concentrations of soluble OVA
or OVA bound to IgGaOVA. Three days after injection
of the antigen, T-cell proliferation in the spleen and
lymph nodes was analysed.
Soluble OVA induces T-cell proliferation when injected
at a concentration of 100 lg/mouse, but no proliferation
was detectable any more when OVA was administrated at
a concentration of 10 lg or lower. In contrast, injection
of OVA incubated with anti-OVA IgG still resulted in sig-
nificant proliferation of DO11.10 cells when injected at a
dose of 01 lg OVA/mouse (Fig. 1). Injection of OVA
incubated with control IgG did not induce proliferation
at a concentration of 10 lg or lower (data not shown).
These results indicate that IC are at least 100 times more
efficient in inducing CD4+ T-cell proliferation than sol-
uble OVA.
 2006 Blackwell Publishing Ltd, Immunology, 119, 499–506
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DC and/or macrophages are the dominant APC that
present IgG-complexed antigen in vivo
DC are known to take up and process IC via FccR. Also
other professional APC, like macrophages and B cells, dis-
play FccR and are thought to present antigen that have
been acquired through FccR.4,5,14,18,21
To test the importance of the different APC in IC-
mediated antigen-presentation to CD4+ T cells directly
in vivo, wild-type and CD11c-DTR transgenic mice were
injected with CFSE-labelled OVA-specific CD4+ T cells
and immunized with IC. CD11c+ DC in the latter mouse
strain can be depleted in vivo by injection of DT.10 As
shown in Fig. 2, injection of IC induces T-cell prolifer-
ation in both mouse strains. Injection of DT into wild-
type mice had no effect on T-cell proliferation (Fig. 2a),
showing that DT does not affect antigen-specific T-cell
proliferation of DO11.10 cells. However, when DC were
depleted in the CD11c-DTR transgenic mice by injection
of DT, proliferation of the T cells was almost completely
abolished (Fig. 2b). Even when a 10 times higher con-
centration of IC was injected, no proliferation was
induced in mice depleted for CD11c+ cells (data not
shown). Until recently, these data indicate that the DC,
but not the macrophages and B cells, are the predomin-
ant cell type responsible for IC-mediated, MHC class II-
restricted CD4+ T cell activation in vivo. However, a
recent publication elegantly showed that DT injection
into these CD11c-DTR transgenic mice also depletes
marginal zone and metallophilic macrophages.22 There-
fore, these experiments can not make a distinction
between the contributions of macrophages versus DC in
the presentation of immune-complexed antigen to CD4+
T cells in vivo, but do show that B cells are not involved
in this process.
Macrophages do capture IC efficiently
As macrophages and B cells readily express FccR, they are
thought to be able to capture IC. To determine whether
macrophages and B cells capture IgG-complexed OVA,
5 lg radioactively labelled (99mTc) OVA or 99mTc-OVA
complexed to anti-OVA IgG was injected into mice.
One hr after injection, spleens were taken and sorted for
the different types of APC (see Materials and methods
and Fig. 3). The time point of 1 hr was chosen as previ-
ous studies have shown that 100% of IC are cleared from
the bloodstream within this period.23 Uptake of IC by the
different APC was analysed by measuring the radioactivity
present in the DC-, macrophage- and B-cell fractions. To
this end, cells were counted and the amount of 99mTc
present per 106 cells was determined. As shown in
Fig. 4(a), a high level of radioactive label was present in
the macrophage-fraction. This was even higher than the
radioactivity measured in the DC-fraction (on a per cell
basis). Although B cells were also able to acquire 99mTc-
IC, the amount of radioactivity measured in the B-cell
fraction was relatively low. 99mTc-OVA, not complexed
with anti-OVA IgG, was hardly detectable in any cell frac-
tion at this concentration.
Figure 1. OVA-IC are at least 100 times more efficient then soluble
OVA in inducing T-cell proliferation. CFSE labelled DO1110 cells
were transferred into mice. These mice were subsequently injected
i.v. with different concentrations of soluble OVA or OVA complexed
to anti-OVA IgG (n ¼ 2). Three days after injection, proliferation of
the DO1110 cells (CD4+/KJI26+) was analysed in the spleen and
lymph nodes (not shown). One representative experiment out of two
performed is presented.
Figure 2. DC and/or macrophages are the predominant cells for
presentation of IgG-complexed OVA to OVA-specific CD4+ T cells
in vivo. CFSE-labelled DO11.10 cells were transferred into wild-type
(a) or CD11c-DTR transgenic mice (b). These mice were or were
not treated with DT, as indicated, and injected i.v. with 1 lg IC
(n ¼ 2). Three days after IC injection, proliferation of the DO11.10
cells (CD4+/KJI26+) was analysed. One representative experiment out
of two performed is presented.
- Chapter 2 -
32
To demonstrate that the 99mTc-labelled IC follows the
same pattern of antigen-presentation as unlabelled IC,
wild-type mice, injected with CFSE-labelled OVA-specific
CD4+ T cells, were infused with labelled- or unlabelled IC
and CD4+ T-cell proliferation was analysed. As shown in
Fig. 4(b), 99mTc-labelling had no apparent effect on the
ability to present immune-complexed antigen. Together,
these results indicate that both macrophages and DC, but
not B cells, are able to capture IC efficiently and further
emphasize the inability of B cells to present immune-
complexed antigen to CD4+ T cells.
Macrophages do not present IC to CD4+ T cells
To gain more insight into the ability of the different types
of APC to capture and present IC to CD4+ T cells, we
infused 5 lg IC i.v. into naive mice. One hr after IC
injection, spleen cells were taken and separated into the
different APC fractions. These APC populations (i.e. DC,
macrophages and B cells) were then analysed for their
ability to induce proliferation of OVA-specific CD4+ T
cells.
Figure 5(a) shows that only the CD11c+ cell fraction,
but not macrophages or B cells, are able to induce prolif-
eration of DO11.10 cells in vitro after administration of
5 lg IC in vivo. Also at relatively high stimulator to
responder cell ratio’s no significant proliferation of T cells
stimulated by macrophages was observed (Fig. 5b). When
OVA-peptide was added to the different APC popula-
tions, all fractions were able to activate DO11.10 cells
(Fig. 5c), indicating that lack of proliferation in the B-cell
and macrophage cultures was not a consequence of an
hampered ability of these cells to present antigen and
activate DO11.10 cells. When soluble OVA was injected
in the same concentration as IC, none of the different
types of APC were able to induce T-cell proliferation
(data not shown). Likewise, peritoneal macrophages
(pMF) loaded in vitro with 1 lg OVA-IC were not able
to activate DO11.10 hybridoma cells unless loaded exo-
genously with free OVA-peptide. In contrast, DC loaded
with the same amount of OVA-IC efficiently activated
DO11.10 cell (Fig. 5d). Together, these results indicate
that the DC, and not the macrophages and B cells, are
the most prominent APC in IC-mediated, MHC class II-
restricted, antigen-presentation.
Discussion
In this study we investigated the ability of DC, macro-
phages and B cells to acquire and present OVA-IC to
Figure 3. Purity of APC populations. Total spleen cells were first
sorted in a CD11c+ (the DC) and a CD11c– fraction (see Materials
and methods). The CD11c– cells were further divided into a
CD11b+-fraction (macrophages) and a GAM+-fraction (B cells). The
purified cell populations contained 922 ± 30% CD11c+ cells (DC),
989 ± 03% CD11c– GAM+ cells (B cells), and 853 ± 26%
CD11c– CD11b+ cells (macrophages).
Figure 4. DC and macrophages are able to capture IC. (a) Wild-
type mice were injected i.v. with 5 lg 99mTc-labelled soluble OVA,
OVA-IC or free 99mTc as control. One hr after injection, spleen cells
were isolated and sorted for DC, macrophages and B cells. The
amount of 99mTc acquired by the cells was subsequently determined.
Data show the counts/20 s/106 cells. One representative experiment
out of two performed is presented. (b) Mice, previously injected with
CFSE-labelled DO11.10 cells, were injected i.v. with the unlabelled or
the 99mTc-labelled IC. Three days after IC injection, proliferation of
the DO1110 cells (CD4+/KJI26+) was analysed in the spleen.
 2006 Blackwell Publishing Ltd, Immunology, 119, 499–506
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OVA-specific CD4+ T cells in vivo. Our results revealed
that DC, but not macrophages or B cells are able to acti-
vate CD4+ T cells efficiently following FccR-facilitated
antigen capture, despite the fact that macrophages readily
capture IC in vivo and express abundant amounts of
FccR, costimulatory molecules and MHC class II mole-
cules (data not shown).21 These results are important as
they show that the predominant cell type able to present
antigen derived from IC to CD4+ T cells is the DC.
Previously, it has been shown that DC efficiently facili-
tate IC-mediated antigen-presentation in the context of
MHC class I molecules.9 However, the pathways leading
to antigen-presentation via MHC class I or class II mole-
cules are distinct.1 MHC class I molecules primarily pre-
sent peptides derived from endogenously synthesized
proteins of either self or pathogen origin. In contrast,
MHC class II molecules generally present peptides derived
from exogenous proteins that enter the cell through the
endocytic route. Nevertheless, exogenous antigen can also
be presented in the context of MHC class I molecules by
DC, as these cells express specialized compartments that
are thought to be involved in antigen-shuttling from end-
ocytic compartments into the cytoplasm and further pro-
cessing for MHC class I.7,13,24 In contrast, internalized
antigen present in the endocytic compartment can be loa-
ded directly onto MHC class II molecules.1 Earlier studies
have shown that all three types of APC (i.e. DC, macro-
phages and B cells) are able to take up and present sol-
uble antigen in vivo.25
Figure 5. DC take up and present IgG-complexed OVA to OVA-
specific CD4+ T cells. Wild-type mice were injected i.v. with 5 lg
OVA complexed to anti-OVA IgG or were left untreated (a). One hr
after injection, spleen cells were isolated and sorted for DC (CD11c+
cells), macrophages and B cells. These cells were subsequently added
to DO1110 cells in a ratio of 2 : 1 (see Materials and methods),
to analyse their ability to stimulate T cells. Proliferation of the
DO1110 cells was determined by [3H]-thymidine incorporation.
(b) The same experiment as described above was performed with
S : R ratios of 3 : 1 and 4 : 1. (c) To control whether the different
isolated APC fractions are able to stimulate T cells, the APC were
incubated with 001 lg/ml, 01 lg/ml or 1 lg/ml OVA peptide (see
Materials and methods). Proliferation of the DO11.10 cells was
determined as described in (a). Error bars indicate SEM of triplicate
wells. One representative experiment out of four performed is pre-
sented. (d) Macrophages (pMF; 50 000; 25 000 and 12 500 cells/well)
isolated from the peritoneal cavity were incubated with 1 lg OVA-
IC and subsequently used for stimulation of 50 000 DO11.10-hybri-
doma cells. Only pMF loaded with OVA-peptide were able to
activate DO11.10 cells. In contrast, DC were able to activate
DO11.10 cells efficiently after incubation with IC. Activation of
DO11.10 cells was detected by the production of IL-2 in the
supernatant using enzyme-linked immunosorbent assay. The OD at
450 nm is depicted. Error bars indicate SEM of triplicate wells. One
representative experiment out of two performed is presented.
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As macrophages and B cells also express FccR, next to
MHC class II and MHC-loading compartments, they are
thought to be able to take up and present IgG-complexed
antigen to CD4+ T cells.5 Although the macrophage frac-
tion was able to induce some T-cell proliferation (stimu-
lation index: 29 versus 123 by DC-fraction) when a very
high dose of IC was injected (i.e. 40 lg, a higher dose is
lethal; unpublished observations), our results indicate that
the ability to present exogenously acquired IC-derived
antigen in the context of MHC class II molecules for acti-
vation of CD4+ T cells is a characteristic that is predom-
inantly confined to DC.
Our findings contrast other reports that show that
macrophages present exogenously loaded IgG-complexed
antigen to MHC class II-restricted T cells in vitro. It has
been reported that targeting of antigen to FccR on activa-
ted macrophages in vitro can bias a T helper 1 (Th1)
response to a Th2-like response.14 In addition, several
in vitro studies demonstrated that also B cells can capture
and present IC via FccR16,18 although others indicated
that FccRII, expressed by B cells is incompetent for endo-
cytosis.26 In all cases, direct evidence that macrophages
and B cells present IgG-complexed antigen in vivo is lack-
ing. Our results in the experiments with radioactive
labelled IC show that macrophages, but not B cells, read-
ily capture IC but hardly activate CD4+ T cells. The
reasons underlying these observations are intriguing, and
are conceivably related to unique features displayed by
DC. It has been shown that DC, but not B cells, can
accumulate antigen for later presentation.27 After expo-
sure to inflammatory signals or other activating signals,
like FccR-cross-linking, newly formed immunogenic
MHC class II-peptide complexes are transported to the
cell surface through the formation of tubules from lyso-
somal compartments that go on to fuse directly with the
plasma membrane.28,29 Although it is not clear whether
this tubule-mediated pathway is unique for DC, tubular
extensions in macrophages and B cells formed in response
to certain activators have not been reported to mediate
transport to the cell surface but instead are thought to
facilitate phagosome–lysosome fusion.30,31 Macrophages
thus seem to function more as scavenger cells, which
quickly remove the IgG-bound antigen from the body,
then as APC for activation of T cells.
Professional APC, particularly macrophages, are playing
a crucial role in the defence against micro-organisms like
bacteria. In several model systems, it has been shown that
macrophages can present bacterial antigen to MHC class
II-restricted T cells. However, in most instances, these
pathogens, like Mycobacterium tuberculosis or Listeria
monocytogenes, are residing inside the macrophages. Thus,
in these cases, rather than that they have been obtained
from exogenous sources, the antigen are from sources
constitutively present inside macrophages, possibly allow-
ing proper antigen-processing and presentation. Although,
several studies indicated the ability of DC to cross-present
antigen for MHC class II, in general, and IC in particular,
it might not be surprising that macrophages are not able
to cross-present IC-derived antigen. An important func-
tion of CD4+ T cells resides in their ability to enhance
macrophage activity to endow the macrophages with the
capacity to kill intracellular pathogens. In case, however,
the antigen is derived from exogenous sources, no such
enhancement is needed, and therefore, in this case, the
macrophage does not need to communicate with CD4+ T
cells.
Macrophages and B cells are also playing a pivotal role
in various autoimmune diseases. Next to their ability to
produce pro-inflammatory cytokines after FcR-triggering,
it is proposed that they are also able to present antigen to
CD4+ T cells.32–35 Although our study is performed under
steady-state conditions, rather than under inflammatory
conditions as found in ongoing autoimmune diseases,
our findings suggest that these professional APC are
not contributing to the induction and perpetuation of
autoimmune diseases through presentation of antigen to
(pathogenic) CD4+ T cells. Therefore, we consider it
more likely that the IC-related contribution of these pro-
fessional APC to autoimmune diseases is associated to
release of pro-inflammatory cytokines and molecules after
FccR-cross-linking, the inefficient clearance of IC, or the
destruction of autoantibody opsonized cells. The ability
to orchestrate and steer the T-cell response is the respon-
sibility of DC, further emphasizing the crucial role of DC
in controlling (ongoing) T-cell responses.
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A Novel Role of Complement Factor C1q in Augmenting the
Presentation of Antigen Captured in Immune Complexes to
CD8 T Lymphocytes1
Nadine van Montfoort,2* Judith M. H. de Jong,2† Danita H. Schuurhuis,*
Ellen I. H. van der Voort,† Marcel G. M. Camps,* Tom W. J. Huizinga,† Cees van Kooten,‡
Mohamed R. Daha,‡ J. Sjef Verbeek,3§ Ferry Ossendorp,3,4* and René E. M. Toes3†
Ag-IgG immune complexes (IC) are efficiently taken up, and Ag-derived peptides are subsequently processed and presented by
APC. In vitro experiments indicate that IgG Fc Receptors (FcR) facilitate the efficient uptake of IC by dendritic cells. Previous
experiments showed that the cross-presentation of Ag-derived peptides after s.c. administration of IC is FcR-dependent. To study
the role of different FcR and complement in MHC class I Ag presentation after i.v. administration, we used mice deficient for
FcRs and complement components. These mice were injected with CFSE-labeled OVA-specific CD8 T cells followed by ad-
ministration of IC composed of OVA and rabbit anti-OVA IgG i.v. to measure MHC class I presentation of OVA-derived peptides.
The Ag presentation was partly reduced in FcR-chain-deficient mice, but not affected in FcRI/II/III-deficient mice, complement
factor C3-deficient mice, or FcRI/II/III  C3-deficient mice. Importantly, CD8 T cell proliferation was significantly reduced
in mice deficient for C1q. This proliferation could be restored when IC were incubated with purified human C1q before injection.
Likewise, purified C1q could strongly enhance the uptake and presentation of IC by dendritic cells in vitro. Heat inactivation
abrogated the C1q-mediated uptake of IC. In addition, in vivo uptake of OVA-IC in the spleen was significantly reduced in
C1q-deficient mice compared with wild-type mice. Together, these results indicate a novel function of C1q, which is present in high
levels in the bloodstream, by directly enhancing the uptake and MHC class I presentation of Ag captured in IC by APC to CD8
T cells. The Journal of Immunology, 2007, 178: 7581–7586.
P rofessional APC, such as dendritic cells (DC),
5 are able to
process and present exogenous Ag in MHC class I, leading
to the activation of naive CD8 T cells, in a process called
cross-presentation (1). DC may acquire exogenous Ag by receptor-
mediated uptake, pinocytosis or phagocytosis. Receptor-mediated
uptake is generally very efficient. Ag may enter DC via a variety
of receptors, such as mannose receptors or IgG Fc receptors
(FcR) (2–5).
We have previously demonstrated that the FcR-mediated up-
take of the model Ag OVA enabled cross-presentation to CD8 T
cells in vitro (5, 6) and that OVA-anti-OVA IgG immune com-
plexes (OVA-IC) are 100-1000-fold more efficiently presented
compared with free OVA protein.
FcR are receptors for the Fc part of Ig, providing a link between
the cellular and the humoral part of the immune response. FcR are
membrane glycoproteins, which belong to the Ig supergene family.
In mice, four types of FcR are described, that is, three activating
receptors, FcRI (CD64), FcRIII (CD16), and FcRIV, and one
inhibitory receptor, FcRII (CD32) (7–9). Activating FcR are
expressed by many cell types of the immune system, particularly
DC, monocytes, macrophages, NK cells, mast cells, eosinophils,
and neutrophils. The inhibitory receptor FcRII is expressed on all
hemopoietic cells, except T and NK cells. When FcRs are cross-
linked by immune complexes (IC), the balance between activation
and inhibition signals determines the cellular response (10).
Next to FcR, also the complement system is known to interact
with IC. Three pathways of complement activation have been de-
scribed: the classical pathway, the alternative pathway, and the
lectin (i.e., mannan-binding lectin and ficolins) pathway (11, 12).
Each pathway has its own activation and recognition mechanism,
resulting in the formation of C3-convertases that cleave the central
complement component C3 into the fragments C3a and C3b. Bind-
ing of C3b enables clearance of pathogens and IC as well as the
generation of the lytic membrane attack complex.
C1q is one of the activator compounds of the classical comple-
ment pathway and plays an important role in the activation of the
classical complement pathway and the clearance of IC from the
circulation (13, 14). It is present in high levels in the bloodstream
(15). C1q contains a collagen-like tail region to which the serine
proteases C1r and C1s are bound, connected to a globular head
region responsible for ligand binding. The heads recognize defined
regions within the CH2 domain of Ag-complexed IgG molecules,
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thereby opsonizing ICs. Upon binding to its ligand, C1q changes
conformation, which leads to the activation of its associated serine
proteases, C1r and C1s.
In vitro, uptake of OVA-IC and cross-presentation of OVA-
derived peptides is FcR-dependent (6). In vivo, s.c. injected IC
are preferably taken up via FcR without the apparent involvement
of the complement system (16). In this study, we analyzed the
contribution of FcR and the complement system in the cross-
presentation of peptides derived from i.v. administered OVA-IC.
Our results identify an important role for C1q in IC uptake and Ag
presentation, as mice deficient for C1q displayed a substantially
reduced ability to present immune-complexed Ag to CD8 T cells.
Materials and Methods
Mice
C57BL/6Kh (B6; H-2b) and OT-I/CD45.1 mice, which have a transgenic
V2V6 TCR specific for the OVA257–264 epitope in the context of H2-K
b,
were bred in the specific pathogen-free animal facility of the Leiden Uni-
versity Medical Center. FcR-chain-deficient mice were provided by Dr. T.
Saito, (Laboratory for Cell Signaling RIKEN Research Center for Allergy
and Immunology, Yokohama, Japan). C3-deficient mice were provided by
Dr. M. C. Carroll (CBR Institute for Biomedical Research, Harvard Med-
ical School, Boston, MA). C1q-deficient mice were kindly provided by M.
Botto (Rheumatology Section, Faculty of Medicine, Hammersmith Col-
lege, London, U.K.) (17). FcRI/II/III-deficient mice and FcRI/II/IIIxC3-
deficient mice were generated in our laboratory. All mice were backcrossed
on a B6 background for at least six generations. The animal experiments
have been reviewed and approved by the animal experimental committee
of Leiden University.
Adoptive transfer of CFSE-labeled OT-1 cells
To follow T cell proliferation in vivo, OT-I/CD45.1 cells labeled with the
intracellular fluorescent dye CFSE (Molecular Probes) were used. Single-
cell suspension from spleen and lymph node cells from OT-I/CD45.1
mice were depleted for DC using CD11c-specific microbeads and the
MACS system (LS columns; Miltenyi Biotec) according to the manufac-
turer’s instructions. Cells were incubated with 5 M CFSE in PBS/0.1%
BSA (Sigma-Aldrich) for 10 min at 37°C. FACS analysis was performed
to assess CFSE labeling efficiency and the percentage of CD8V2 cells
in the OT-1 donor-derived population. Wild-type (WT) or knockout (KO)
recipients were injected with OT-1 cells containing a standardized number
of 3  106 CD8V2 cells in 200 l PBS/0.1% BSA i.v.
Generation of OVA IC for i.v. injection
IC were generated by incubating OVA (Worthington Biochemical) with
polyclonal OVA-specific rabbit IgG (rIgGOVA; Valeant Pharmaceuti-
cals), at a ratio of 1 g OVA to 50 g rIgGOVA in PBS, for 30 min at
37°C. IC containing 1 g OVA were injected i.v. into the WT or the KO
mice, 1 day after infusion of the OT-1 cells.
For the experiments described later (see Fig. 5B), IC were incubated
with purified human-derived C1q (25 g hC1q/1 g IC) for 1 h at room
temperature before i.v. administration. C1q was obtained as described (18).
Analysis of CD8 T cell proliferation in vivo
To analyze proliferation of the CD8 T cells derived from OT-I/CD45.1
mice in vivo, spleens were collected from the recipient mice 3 days after
the injection of OVA-IC. Spleen cells were incubated with allophycocya-
nin-coupled anti-CD8 Ab and PE-coupled anti-CD45.1 Ab (BD Pharm-
ingen) and analyzed using a FACSCalibur flow cytometer equipped with
CellQuest software (BD Biosciences). Live CD8/CD45.1 T cells were
gated and the CFSE division profile was analyzed. The contribution of the
different FcR and complement was assessed by comparing CD8 T cell
proliferation between the KO mouse strains and the WT controls included
in each experiment.
Uptake of Alexa Fluor488-conjugated OVA (OVA-Alexa488)
by DC
D1 cell line DC were cultured as described (19). OVA-Alexa488-IC were
generated by incubating 1 g/ml OVA-Alexa488 (Molecular Probes) with
50 g/ml polyclonal rIgGOVA (Valeant Pharmaceuticals) for 30 min at
37°C. OVA Alexa488 in IC were incubated with different concentrations of
hC1q for 1 h at room temperature in a flat-bottom 96-well plate. In the
experiments using heat-inactivated C1q, the C1q molecules were, before
adding to the IC, incubated for 60 min at 56°C. After 1 hour, 100,000 D1
cells were added to each well to incubate with the IC and C1q for 1 h at
37°C. After 1 hour, cells were washed intensively to remove IC and C1q.
Cells were then analyzed by FACS.
Cross-presentation of OVA-IC by DC in vitro
IC were generated by incubating OVA (Worthington Biochemical) with
polyclonal rIgGOVA (Valeant Pharmaceuticals), at a ratio of 1 g OVA
to 50 g rIgGOVA in PBS, for 30 min at 37°C. OVA-IC were incubated
with different concentrations of hC1q for 1 h at room temperature in a
flat-bottom 96-well plate. In the experiments using heat-inactivated C1q,
the C1q molecules were, before adding to the IC, incubated for 60 min at
56°C. After 1 hour, 50,000 D1 cells were added to each well to incubate
with the IC and C1q for 1 h at 37°C. After 1 hour, cells were washed
intensively to remove IC and C1q and subsequently incubated with 5  104
B3Z T cells overnight at 37°C. B3Z hybridoma cells recognize the OVA
CTL epitope (SIINFEKL) in H-2Kb and express the lacZ reporter gene
behind the IL-2 promoter (6, 20). Ag presentation is quantified in a col-
orometric assay at an optimal density of 590 nm by adding the substrate
chlorophenol red--D-galactopyranoside to B3Z cell lysates.
Uptake of OVA-Alexa488 by DC in vivo
WT or C1q-deficient mice were injected i.v. with 1 g of OVA-Alexa488
in IC. After 1 h, the mice were sacrificed and the spleens were isolated.
FIGURE 1. Efficient presentation of Ag captured in IC to CD8 T cells.
CFSE-labeled OVA-specific OT-1/CD45.1 cells were transferred into B6
mice. The following day, these mice were injected i.v. with different
amounts of free OVA or OVA complexed with rabbit anti-OVA IgG
(OVA-IC) (n  2). Three days after injection, proliferation of the CD8/
CD45.1 T cells was analyzed in the spleen. One experiment of three
providing similar results is presented.
FIGURE 2. Activating FcR are partly, but not crucially, involved in
the presentation of OVA-IC to CD8 T cells after i.v. injection. CFSE-
labeled OVA-specific OT-1/CD45.1 cells were transferred into recipient
mice. These mice were injected i.v. with 1 g or 10 g OVA-IC. Three
days after injection, proliferation of the CD8/CD45.1 T cells was ana-
lyzed in the spleen. FcR-chain-deficient mice (n  5) as recipients were
compared with WT mice (n  5). One experiment of two providing similar
results is presented.
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Splenocytes were incubated with anti-CD11c-allophycocyanin and ana-
lyzed by FACS. CD11c cells were gated and the percentage of OVA-
Alexa488-positive cells was calculated.
Results
Efficient presentation of Ag captured in IC to CD8 T cells
We and others have previously demonstrated that the uptake of IC
composed of the model Ag OVA bound to OVA-specific IgG en-
abled cross-presentation of OVA-derived peptides to CD8 T cells
(6, 21). In vitro, peptides derived from OVA-IC are much more
efficiently presented than peptides from noncomplexed Ag in a
FcR-mediated fashion. In vivo, we have shown that FcR are
involved in IC-mediated Ag-presentation when the IC are admin-
istered s.c. (16). Likewise, it has been shown that FcR are cru-
cially involved in IgG-mediated enhancement of Ab responses af-
ter i.v. immunization with IgG/Ag complexes (22). In this study,
we analyzed IC-mediated Ag-presentation to CD8 T cells after
i.v. administration.
MHC class I Ag presentation of OVA-derived peptides in vivo
was analyzed by using CD8 T cells derived from OT-I/CD45.1
transgenic mice, which have a transgenic TCR specific for the
OVA257–264 epitope as presented by H2-K
b.
WT B6 mice were infused i.v. with CFSE-labeled OVA-specific
T cells, and after 24 h were injected i.v. with different amounts of
free OVA or OVA bound to rIgGOVA. Three days after injection
of the Ag, T cell proliferation in the spleen was analyzed.
T cell proliferation could be induced when free OVA was ad-
ministered at a dose of 100 g/mouse (Fig. 1). No proliferation
was detected when noncomplexed OVA was administrated at
doses of 10 g/mouse or lower. In contrast, i.v. injection of OVA
incubated with anti-OVA IgG resulted in significant proliferation
of OT-I cells at 1 g OVA/mouse. These results indicate that OVA
complexed with anti-OVA IgG in IC administered i.v. is 10 to 100
times more efficient in inducing CD8 T cell proliferation than
noncomplexed OVA.
Reduced Ag presentation in the FcR-chain-deficient mice, but
not in FcRI/II/III-deficient mice
FcR -chain-deficient mice lack the expression of activating FcR
(23). We analyzed the involvement of the activating FcR in the
presentation of immune-complexed OVA after i.v. injection. As
shown in Fig. 2, CD8 T cell proliferation was partly reduced in
the FcR-chain-deficient mice compared with CD8 T cell pro-
liferation in WT mice after injection of 1 g IC, while no differ-
ences were observed at 10 g IC. To obtain a better appreciation
of the FcR responsible for the diminished Ag presentation in the
absence of activating FcR, we analyzed the ability of FcRI/II/III-
deficient mice to facilitate Ag presentation to CD8 T cells. In
FcRI/II/III-deficient mice, only the newly described FcR IV (7)
is present. As shown in Fig. 3, no apparent differences in Ag pre-
sentation were observed between the FcRI/II/III-deficient mice
and WT mice after i.v. injection of 1 g IC. These results together
indicate that, after i.v. injection of IC, activating FcR are in-
volved in presentation of the Ag to CD8 T cells, however other
receptors or mediators are likely to play a role as well.
The central complement component C3 is not crucial for
presentation of Ag from IC to CD8 T cells
Because circulating IC interact with complement components, and
professional APC express receptors for several complement fac-
tors, we studied the involvement of complement in the presentation
of OVA-IC to T cells. C3 has a central role in the activation of the
complement system, because all three pathways are dependent on
the presence of C3.
As shown in Fig. 4, no difference in CD8 T cell proliferation
was found between WT and C3-deficient mice when injected with
IC i.v. These results, therefore, indicate that C3, or those compo-
nents that are activated directly or indirectly by the action of C3,
do not play a crucial role in IC-mediated Ag-presentation to CD8
T cells.
As it is conceivable that the system is redundant, we also ana-
lyzed the CD8 T cell proliferation in mice deficient for both the
FcR and C3 (FcRI/II/III/  C3/) after i.v. injection of IC.
Again, no changes in T cell proliferation were found (Fig. 4),
indicating that neither the FcRI, FcRII, FcRIII, nor C3, or the
molecules downstream from C3, are involved in IC-mediated Ag-
presentation after i.v. administration of the IC.
C1q is crucially involved in IC-mediated Ag presentation in vivo
IC activate the complement system via interaction with C1, the
first component of the classical complement pathway. C1q is
present in high levels in the bloodstream. One of the major roles
for C1q is the clearance of IC from the circulation. To examine the
FIGURE 3. FcRI/II/III are not crucially involved in the presentation of
OVA-IC to CD8 T cells after i.v. injection. CFSE labeled OVA-specific
OT-1/CD45.1 cells were transferred into recipient mice. FcRI/II/III/
mice (n  4) as recipients were compared with wild-type mice (n  4).
These mice were injected i.v. with 1 g or 10 g OVA-IC. Three days after
injection, proliferation of the CD8/CD45.1 T cells was analyzed in the
spleen.
FIGURE 4. C3 is not required for the presentation of OVA-IC to CD8 T cells after i.v. injection. CFSE-labeled OVA-specific OT-1/CD45.1 cells
were transferred into WT mice, C3/ mice, or FcRI/II/III/  C3/ mice. These mice were injected i.v. with 1 g or 10 g OVA-IC (n  4). Three
days after injection, proliferation of the CD8/CD45.1 T cells was analyzed in the spleen.
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possibility that C1q is also involved in the presentation of the
OVA-derived antigenic peptide after i.v. injection of OVA-IC,
CD8 T cell proliferation was analyzed in mice deficient for C1q.
As shown in Fig. 5, proliferation of the OVA-specific CD8 T
cells was strongly reduced in C1q-deficient mice compared with
WT mice after injection of 1 g IC i.v. No changes in proliferation
were found when high amounts (100 g) of OVA protein were
administrated i.v. in soluble form, indicating that DC from C1q-
deficient mice are not generally deficient in endocytosis, process-
ing, and presentation of Ag. In addition, no intrinsic abnormalities
in the uptake of IC by primary DC cultures derived from C1q KO
mice were observed (data not shown).
When the IC were first incubated with purified hC1q before
injection into the C1q-deficient mice, proliferation of the CD8 T
cells was restored (Fig. 5B). These results indicate that C1q plays
a prominent role in IC-mediated Ag presentation.
C1q enhances the uptake and Ag presentation of IC by DC
in vitro
To determine the efficiency of OVA uptake by DC, we developed
a system using fluorescent OVA-Alexa488 protein to measure up-
take by FACS. In this way, we show that C1q can strongly enhance
the uptake of IC by DC (Fig. 6A). Alexa488-labeled IC were in-
cubated with different concentrations of human C1q and added to
DC in vitro. After 1 hour, the uptake of IC by the DC was mea-
sured. The uptake of IC at an OVA concentration of 0.5 g/ml or
higher is greatly enhanced when increasing amounts of C1q were
added (Fig. 6B). The C1q binding activity is mediated via the
globular heads of the C1q molecule, which can interact with the
constant domain of the IgG molecule. The binding function of
these globular heads is classically heat sensitive. As shown in Fig.
6C, the enhancement of IC uptake by DC in combination with C1q
is abrogated when C1q is heat-inactivated at 56°C. C1q-mediated
enhancement of IC uptake by DC resulted in improved MHC class
I presentation of the OVA-derived SIINFEKL epitope (Fig. 6D).
This enhancement of MHC class I presentation was also abrogated
by heat inactivation of C1q. These results together indicate that
C1q is actively involved in the MHC class I presentation of pep-
tides derived from circulating immune-complexed Ag.
Decreased uptake of OVA-IC in splenic DC of C1q-deficient
mice after i.v. injection
To analyze whether C1q also enhances the uptake of IC by DC in
vivo, we injected C1q-deficient and WT mice with OVA-
Alexa488-IC. In the C1q-deficient mice, significant lower numbers
of CD11c cells have taken up OVA-IC (Fig. 7). These results
correlate with our findings obtained in vitro, indicating a direct
effect of C1q in the enhancement of uptake of circulating IC. These
results also indicate that the reduced Ag presentation in vivo in the
absence of C1q is related to decreased uptake of circulating IC by
FIGURE 5. C1q is crucially involved in the presentation of OVA-IC to
CD8 T cells after i.v. injection. CFSE-labeled OVA-specific OT-1/
CD45.1 cells were transferred into WT mice (n  3) or C1q/ mice
(n  3). These mice were injected i.v. with 1 g or 10 g OVA-IC or 100
g of free OVA (n  3) (A) or 1 g OVA-IC  25 g/ml purified human-
derived C1q (B). Three days after injection, proliferation of the CD8/
CD45.1 T cells was analyzed in the spleen. One experiment of three (A)
or two (B) performed, providing similar results, is presented.
FIGURE 6. C1q enhances uptake and cross-presentation of immune-
complexed Ag by DC in vitro. A–C, DC were incubated for 1 hour with (A)
medium (thin line), 1 g/ml OVA-Alexa488 in IC (thick gray line), or 1
g/ml OVA-IC that were also incubated with 0.5 g/ml purified human
C1q before the addition to DC (thick black line); (B) different concentra-
tions of OVA-Alexa488 in IC preincubated with increasing concentrations
of purified human C1q (x-axis); (C) 1 g/ml OVA-Alexa488 in IC prein-
cubated with increasing concentrations of purified human C1q (f) or pu-
rified human C1q that was heat-inactivated at 56°C (Œ). After 1 hour, DC
were harvested and analyzed by FACS for Alexa488 fluorescence (y-axis).
D, DC were incubated for 1 hour with 1 g/ml OVA-IC preincubated with
increasing concentrations of human C1q (f) or human C1q that was heat-
inactivated at 56°C (Œ). After 24 h, B3Z OVA-specific CD8 T cells were
added overnight, and Ag presentation was measured in a colorimetric assay
at optimal density 590 nm (see Materials and Methods).
FIGURE 7. Decreased uptake of OVA-IC in splenic DC of C1q-defi-
cient mice after i.v. injection. WT or C1q/ mice (n  2) were injected
i.v. with 1 g of OVA-Alexa488 in IC. After 1 h, the mice were sacrificed
and the spleens were isolated. CD11c spleen cells were analyzed on
OVA-Alexa488 uptake by FACS analysis. Student t test was performed to
assess the difference, p  0.01. The experiment was performed three times
with similar results.
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splenic DC. Together, these findings indicate that C1q facilitates
the presentation of peptides derived from immune-complexed Ags
to CD8 T cells by enhancing the DC-mediated uptake of IC.
Discussion
In this study, we investigated the contribution of the different mu-
rine FcR and complement to the activation of OVA-specific
CD8 T cells in vivo following i.v. vaccination with OVA-IC.
Previously, it has been shown that the protein Ag contained
within the IC is much more efficiently processed and presented in
MHC molecules than free Ag by DC in vitro (6, 21). In this study,
we also show that i.v. injected immune complexed-Ag is presented
more efficiently than noncomplexed Ag in vivo. The presentation
of IC after i.v. administration is partly dependent on activating
FcR, however it is not crucially dependent. This is in agreement
with an earlier publication, where it was shown that the ability of
CD8 DC, in contrast to CD8 DC, to induce CD8 T cell pro-
liferation was not affected in FcR-chain/ mice after i.v. injec-
tion with IC (24).
Our results indicate a pivotal contribution of C1q in the presen-
tation of Ag derived from i.v. administered IC to CD8 T cells in
vivo, indicating that C1q can accommodate the presentation of Ag
complexed in IC. The enhancing effect, mediated by C1q in the
presentation of immune complexed Ag in vivo, might be a conse-
quence of an altered clearance of IC from the blood in C1q-defi-
cient mice, as it has been shown that the splenic uptake of IC is
significantly reduced in mice deficient for C1q (14). Although an
altered clearance or deposition of IC could certainly contribute to
the effects observed in vivo, our results obtained in vitro indicate
that C1q-binding to IC also directly enhances the uptake and pre-
sentation of Ag from IC by DC. Because immature DC are a
source of C1q (18), the direct enhancement may be mediated at the
local environment in the tissue.
Although we cannot formally conclude that C1q plays a similar
role in vivo under unmanipulated conditions involving all murine
ingredients, we consider it unlikely that the findings are a conse-
quence of using rabbit IgG and human C1q: complement compo-
nents are highly conserved and can bind and be activated by rabbit
IgG, as shown, for example, by the replaceability of human C1q
and murine C1q in hemolytic assays (25) and the ability of murine
C3 to be deposited on rabbit IgG following complement activation
(26). Likewise, murine FcR can readily interact with rabbit Ig IC,
as shown by their crucial role in the cross-presentation of immune-
complexed Ag in vitro (5) and after s.c. administration of IC (16).
Moreover, we have shown in vitro that the uptake of IC by DC is
similar when mouse Ig is used instead of rabbit Ig (data not
shown). Adding hC1q to the IC composed of mouse IgG gave a
similar enhanced uptake (data not shown) as seen with IC com-
posed of rabbit IgG (Fig. 6, B and C).
As the enhanced uptake of Ag in IC was abolished after inac-
tivating C1q at 56°C, which results in the melting of the globular
heads of the molecule, it is likely that intact globular heads are
crucial for the enhancement of uptake. The globular heads of C1q
are shown to bind to the CH2 domain in the Fc-tail of the Ab (13),
indicating that C1q directly influences the stability, composition,
or size of the IC, thereby enhancing the binding and presentation
of IC by DC.
In line with our findings, C1q has been shown to enhance the
phagocytosis of apoptotic cells, pathogens, and opsonized eryth-
rocytes in a dose-dependent way (27–31). The enhancement of the
uptake of opsonized erythrocytes could be blocked by anti-C1q
Abs, and was only observed when the collagenous part of C1q was
present, indicating that an interaction of C1q with a C1q receptor
was involved in the enhancement. To date, several types of puta-
tive C1q-binding cell surface-expressed receptors have been de-
scribed (13, 32–37). Although the receptors are shown to interact
with C1q, so far they are not described to mediate the enhanced
endocytosis of IC. If the C1q-dependent enhancement of uptake
requires an interaction of C1q with one of the candidate receptors,
it is most likely that the collagen-like region of C1q binds the
receptor(s) (38). However, the globular heads cannot be ruled out
as a ligand, because the binding of C1q to the Fc region involves
only two of the six globular heads, leaving room for unoccupied
heads to bind to other molecules, including receptors. Therefore,
based on our in vitro results and the literature discussed, a direct
effect of C1q on the conformation of the IC, the clearance of IC in
vivo, and/or the involvement of candidate C1q receptors that in-
teract with C1q and/or synergize with FcR may be involved in the
enhanced C1q-dependent presentation of peptides derived from
immune complexed Ag.
In conclusion, we have shown that C1q, which is present in high
levels in the bloodstream, plays a pivotal role in the cross-presen-
tation of IC-derived peptides to CD8 cells in vivo after i.v. ad-
ministration, thereby bridging innate and adaptive immune re-
sponse. This novel function of C1q may be of relevance for the
design of improved vaccination strategies against infectious dis-
eases and cancer.
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- Chapter 4 -Antigen(Ag)–immunoglobulin (Ig)G complexes (IC) are more efficiently processed and presented than soluble Ag. IC can bind to various cell
ypes via different types of Fc-Receptors or, upon binding to complement factors, by complement receptors. Murine professional antigen-presenting
ells (APC) express four types of FcReceptors (FcR) via which they are able to capture IC; three activating receptors (FcRI, III and IV) and
ne inhibitory receptor (FcRII). It has been demonstrated that FcR play a pivotal role in facilitating the presentation of Ag derived from IC.
onetheless, relative little information is available on the relative contribution of the activating or inhibitory FcR or complement to the presentation
f immune-complexed Ag to CD8+ T cells.
To study the contribution of the different FcR and complement receptors in IC-facilitated Ag-presentation, we analyzed the ovalbumin(OVA)-
pecific CD8+ T cell proliferation in FcR- and complement component 3 (C3)-deficient mice after subcutaneous injection of OVA-IC. Here
e show that the efficient Ag-presentation was FcR-, but not C3-mediated, as it was inhibited in FcRI/II/III-deficient mice but unaffected in
he C3-depleted mice. Moreover, FcRIV does not play a role under these conditions. However, no difference was found between wild-type and
cRI/III-deficient or wild-type and FcRII-deficient mice. These results indicate that Ag-presentation via the activating FcR is not enhanced in the
bsence of FcRII, and point to redundancy of the FcR, including FcRII, in the uptake and presentation of s.c. injected soluble IC to CD8+ T cells.
2006 Elsevier Ltd. All rights reserved.
eywords: FcReceptors; Immune complexes; Antigen presentation; CD8+ T cells
. Introduction
MHC class I molecules are generally complexed with pep-
ides derived from newly synthesized cytosolic proteins. How-
ver, professional APC are also able to process and present
Abbreviations: Ag, antigen; APC, antigen presenting cells; BSA, bovine
erum albumin; C3, complement component 3; CFSE, 5(6)-carboxyfluorescein
iacetate succinimidyl ester; CVF, cobra venom factor; FcR, receptor for the
c part of the IgG molecule; FCS, fetal calf serum; IC, immunecomplexes;
g, immunoglobulin; ITAM, immunoreceptor tyrosine-based activation motif;
TIM, immunoreceptor tyrosine-based inhibitory motif; OVA, ovalbumin; PBS,
hosphate-buffered saline
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exogenous antigens leading to the activation of naı̈ve CD8+
T cells. Ag derived from apoptotic cells, antigen-heat shock
protein-complexes and Ag-immunoglobulin (Ig)G complexes
(IC) are shown to be presented by DC to T cells in a process
called cross-presentation (Heath and Carbone, 2001). For the
uptake of exogenous antigen, DC display several receptors like
mannose-receptors, CD91, CD36, complement receptors and
FcReceptors (FcR).
FcR are receptors for the Fc part of the constant region of Ig,
providing a link between the cellular and the humoral part of
the immune response. FcR are membrane glycoproteins, which
belong to the Ig supergene family. There are different FcR for
each Ig class: FcR (IgA), FcR (IgE), FcR (IgG) and Fc/R
(IgA and IgM).
In mice, four types of FcR are described, i.e. three activat-
ing receptors, FcRI (CD64), FcRIII (CD 16), and the recently
161-5890/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
oi:10.1016/j.molimm.2006.01.002
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identified FcRIV (Mechetina et al., 2002; Nimmerjahn et al.,
2005), and one inhibitory receptor, FcRII (CD32) (Ravetch
and Kinet, 1991; Ravetch and Bolland, 2001). The activating
FcR are associated with the signal transducing -chain (FcR)
homodimer, which contains an immunoreceptor tyrosine-based
activation motif (ITAM) in its cytoplasmic tail. In contrast,
the inhibitory FcR is a single-chain receptor containing an
immunoreceptor tyrosine-based inhibitory motif (ITIM) in its
cytoplasmic domain.
Activating FcR are expressed by most effector cells of
the immune system, particularly monocytes, macrophages, NK
cells, mast cells, eosinophils, and neutrophils, while absent from
lymphoid cells. The inhibitory receptor FcRII is expressed on
all hematopoietic cells except T and NK cells. In general, acti-
vating and inhibitory FcR are co-expressed on the same cell.
The IgG ligand will then be able to cross-link both receptor
types, which is important for setting a threshold for activating
stimuli. The relative expression of these two opposing signaling
systems is likely to determine the cellular response (Ravetch
and Clynes, 1998). B cells only express FcRII on their sur-
face. Here, FcRII inhibits Ab responses to IgG-complexed Ag
when it is co-ligated to the BCR (Ravetch and Bolland, 2001).
Although FcR are important to facilitate presentation of Ag
complexed in IC, the relative contribution of the different FcR
or the possible negative regulation mediated by FcRII on this


























the OVA257–264 epitope in the context of H2-Kb, were bred
in our specific pathogen-free animal facility. FcRI/II/III-
deficient mice, FcRI/III-deficient mice, FcRII-deficient mice
and their wild-type counterparts were generated in our
own laboratory. C3-deficient mice and FcR-chain-deficient
mice were kindly provided respectively by Dr. Carroll and
Dr. Saito.
2.2. Depletion with cobra venom factor
To deplete complement factors in vivo, B6 mice were injected
twice i.p. with 500 Units Cobra Venom Factor (CVF; Naja naja
Kaoutchia; MP Biomedicals, Aurora, OH). The second injection
took place 6 h after the first. To determine whether complement
factors were depleted, serum of these mice was analyzed next
day by ELISA for C3.
2.3. CFSE labeling
To follow T cell proliferation in vivo, OT-I/Ly5.1+ cells were
labeled with the intracellular fluorescent dye CFSE (Molec-
ular Probes, Leiden, the Netherlands). Spleen and lymph
node cells from OT-I/Ly5.1+ mice were depleted for dendritic
cells using CD11c-specific microbeads and the MACS sys-
tem (LS+ columns) (Milteny, CLB, Amsterdam, The Nether-


























- Chapter 4 -Mice-deficient for the different FcR provide excellent tools
o analyze the specific contribution of the individual FcR to
gG-dependent immune functions (Ioan-Facsinay et al., 2002;
azenbos et al., 1996). To study the relative contribution of the
our different FcR in facilitating presentation of IC-derived Ag,
e analyzed the activation of OVA-specific CD8+ T cells (OT-
) upon subcutaneous injection of OVA-IC in FcR knock out
nd wild-type mice. Previous studies have already shown that
g internalized through FcR are more efficiently presented to
cells (Lanzavecchia, 1996; Regnault et al., 1999; Hamano et
l., 2000). Our results confirm that IgG-complexed OVA is at
east 10 times more efficient than soluble OVA in activating Ag-
pecific CD8+ T cells in vivo. We now also show that this effect
s absent in mice lacking FcRI, II and III, but not in C3-deficient
ice, indicating that the enhanced efficiency was complement
ndependent and primarily FcR mediated but independent of
cRIV. However, no difference was found between wild-type
nd FcRI/III-deficient mice, between wild-type and -chain-
eficient mice or between wild-type and FcRII-deficient mice.
These results indicate that the activating receptors FcRI and
cRIII as well as the inhibiting FcRII can mediate the uptake
nd presentation of IC to T cells and illustrate that the activation
f CTL via IC uptake by the activating FcRI and FcRIII is
ot enhanced in the absence of the inhibitory FcRII.
. Materials and methods
.1. Mice
C57BL/6Kh (B6; H-2b) mice and OT-I/Ly5.1 transgenic
ice, which have a transgenic V2V5 TCR specific for
48ashed with PBS containing 0.1% bovine serum albumin
BSA; Sigma–Aldrich, Zwijndrecht, the Netherlands) and resus-
ended to 10 × 106 cells/ml in PBS/0.1% BSA with 5 M
FSE for 10 min at 37 ◦C. Ten percent heat-inactivated fetal
alf serum (FCS; Bodinco, Alkmaar, the Netherlands) was
dded and cells were washed twice with IMDM (BioWhit-
aker, Europe), supplemented with 8% FCS, 100 IU/ml peni-
illin/streptavidin (BioWhittaker), 2 mM l-glutamine (Invitro-
en, Breda, the Netherlands) and 20 M 2-mercaptoethanol
Merck, Hohenbrunn, Germany), and resuspended in PBS/1%
SA. 3 × 106 CD8+V2+V5+ OT-I cells in 200 l PBS/0,
%BSA were injected i.v. into the mice.
.4. Generation of OVA immune complexes
Immune complexes were generated by incubating soluble
VA (Sigma–Aldrich) with polyclonal OVA-specific rabbit IgG
rIgGOVA) (MP Biomedicals), at a ratio of 1 g OVA to 25 g
IgGOVA in PBS, for 30 min at 37 ◦C. IC were then injected
.c. into the right flank of the mice.
.5. Antibodies
To analyze proliferation of the OT-I cells in vivo, draining
nd non-draining lymph nodes were collected from the mice.
ymph node cells were stained with APC-coupled anti-CD8
b (Ly-2) and PE-coupled anti-CD45.1 Ab (Ly5.1) (both from
harMingen, San Diego, CA). Stainings were performed for
0 min at 4 ◦C. CFSE+CD8+Ly5.1+ cells were analyzed using
FACSCalibur® flow cytometer equipped with CellQuest soft-
are (Becton Dickinson, San Jose, CA).
Fig. 1. IC are at least 10 times more efficient then soluble OVA in inducing T cell proliferation. CFSE labeled OT-I/Ly5.1+ cells were transferred into wild-type mice.
These mice were subsequently injected s.c. with different concentrations of soluble OVA or OVA complexed to anti-OVA IgG (n = 2). Three days after injection,
proliferation of the CD8+/Ly5.1+ T cells was analyzed in the draining and non-draining lymph nodes. One representative experiment out of three performed is
presented.
3. Results
3.1. Efficient IC-mediated CD8+ T cell proliferation in vivo
Professional APC are able to capture, process and present
exogenous Ag leading to activation of T cells. Several in vitro
studies showed that Ag complexed with IgG are much more
efficiently presented than soluble Ag in a FcR-mediated fashion
(Amigorena and Bonnerot, 1999; Manca et al., 1991). To confirm
and extend these data, wild-type mice were injected i.v. with
CFSE labeled OVA-specific T cells derived from OT-I/Ly5.1+
mice and treated s.c. with different concentrations of soluble
OVA or OVA bound to IgGOVA. Three days after injection
of the antigen, T cell proliferation in the draining lymph and
non-draining nodes was analyzed.
In some, but not all mice, soluble OVA induced T cell prolifer-
ation in the draining lymph nodes when a dose of 10 g/mouse
(data not shown) was injected. No proliferation was detected
when a dose of 1 g/mouse or lower soluble OVA was admin-
istrated (Fig. 1). In contrast, injection of OVA incubated with
anti-OVA IgG still resulted in significant proliferation of OT-I
cells in the draining lymph nodes even when injected at a dose of
0.1 g OVA/mouse. These results indicate that subcutaneously
given IC are at least 10 times more efficient in inducing CD8+









As shown in Fig. 2A and B, CD8+ T cell proliferation was
strongly reduced in the FcyRI/II/III−/− mice compared to the
T cell proliferation in wild-type mice after injection of 0.1 g
IC. No difference in T cell proliferation was observed between
wild-type mice and mice treated with cobra venom factor, which
depletes active C3 and C5 and thereby inhibits the effector func-
tion of the complement system (Fig. 2C). Similar results were
obtained in the C3−/− mice (data not shown). Together, these
results indicate that, after s.c. injection of IC, FcR play the
most prominent role in uptake and presentation of Ag to CD8+
T cells, while activation of C3 does not seem to be involved in
this process.
3.3. No difference between WT and FcγRI/III-deficient
mice
To investigate the contribution of the three activating FcR,
FcRI, III and IV, to IC-facilitated Ag-presentation in vivo, T cell
proliferation was compared between wild-type and -chain−/−
mice, which lack FcRI, III and IV, upon immunization with IC.
As shown in Fig. 3A, no difference in CD8+ T cell proliferation
was found between wild-type en -chain−/− mice when immu-
nized with IC s.c. However, recent publications suggest that the
-chain−/− mice still express low amounts of FcRI (Barnes et









- Chapter 4 -.2. FcγR are involved in IC-mediated Ag-presentation, C3
s not
Uptake of IC can be mediated via FcR, from which there are
our types known in mice: FcRI, II, III and IV. Alternatively,
omplement factors can form complexes with IC that subse-
uently can be taken up via complement receptors. To analyze
hich receptors are most important in IC uptake and presenta-
ion in vivo, Ag-presentation after injection of IC was analyzed
n different FcR-deficient and C3-deficient mice.n the FcyRI/III mice. Fig. 3B shows that also in these mice,
roliferation of the CD8+ T cells was equally efficient in wild-
ype and FcyRI/III−/− mice. Thus, FcRI, III and IV are not
rucial for IC-mediated activation of OVA-specific CTL.
.4. FcγR seem to be redundant
As there is a reduced T cell proliferation in the FcyRI/II/III−/−
ice upon s.c. injection of IC, which is not observed in -
hain−/− and FcyRI/III−/− mice, we also wished to analyze the
ontribution of FcRII to this process. Therefore, CD8+ T cell
49
Fig. 2. Reduced T cell proliferation in FcRI/II/III-deficient mice. CFSE labeled
OT-I/Ly5.1+ cells were transferred into wild-type mice, FcyRI/II/III−/− mice (A
and B) or Cobra Venom Factor treated mice (C). These mice were injected s.c.
with different concentrations of IC (n = 2). Three days after injection, prolifer-
ation of the CD8+/Ly5.1+ T cells was analyzed in the draining lymph nodes.
One experiment out of four (A and B) or two (C) performed is presented. B: In
next figures the results will be shown in column graph as follow: the percentage
of cell that are proliferating (2) from the total amount of CD8+/Ly5.1+ cells
(1). (A) would than look as shown here. One bar of the diagram represents the
average S.D. of two animals per group. One experiment out of four performed
is presented.
Fig. 3. No change in T cell proliferation in -chain-deficient mice and in
FcRI/III-deficient mice. CFSE labeled OT-I/Ly5.1+ cells were transferred into
wild-type mice, -chain−/− mice (A), or FcyRI/III−/− mice (B). These mice
were injected s.c. with different concentrations of IC (n = 3 for -chain−/−, n = 4
for FcyRI/III−/−). Three days after injection, proliferation of the CD8+/Ly5.1+
T cells was analyzed in the draining lymph nodes. One experiment out of three
performed is presented.
proliferation in FcyRII−/− mice was analyzed after s.c. injection
of IC. As shown in Fig. 4, there was also no change in T cell
proliferation in mice lacking FcRII, compared to wild-type
mice. Because the absence of FcRII does not lead to enhanced
Fig. 4. No change in T cell proliferation in FcRII-deficient mice. CFSE labeled
OT-I/Ly5.1+ cells were transferred into wild-type or FcyRII−/− mice. These mice
were injected s.c. with different concentrations of IC (n = 4). Three days after
injection, proliferation of the CD8+/Ly5.1+ T cells was analyzed in the draining
lymph nodes. One experiment out of three performed is presented.
- Chapter 4 -
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activation of CD8+ T cells following s.c. injection of IC, these
findings indicate that FcRII does not inhibit IC-facilitated
CD8+ T cell activation. Moreover, these observations indicate
redundancy of the FcR in the uptake and presentation of IC to
CD8+ T cells, as the lack of three FcR (FcRI, II and III) did
lead to a reduced CD8+ T cell proliferation, whereas the lack
of one or two of these receptors did not.
4. Discussion
In this study, we investigated the contribution of the differ-
ent murine FcR and complement receptors to the activation
OVA-specific CD8+ T cells in vivo, following s.c. vaccination
with OVA-IC. Previously, it has been shown that IC are much
more efficiently presented than soluble OVA in a FcR-mediated
fashion (Amigorena and Bonnerot, 1999; Manca et al., 1991).
In vitro data support that the enhancement of MHC class I-
restricted Ag-presentation is mediated by the activating FcR
(FcRI and FcRIII), as -chain−/− DC are not activated by
IC, and do not present IC-derived MHC class I-binding peptides
more efficiently than peptides derived from soluble Ag alone
(Regnault et al., 1999). Our results show that, also in vivo, FcR,
but not C3, are involved in IC-mediated Ag-presentation. How-
ever, in contrast to the studies described above, FcR (including






























effect of FcRII on FcR-mediated Ag-presentation as it is
shown that DTH reactions take place normally in FcyRII−/−
animals (Getahun et al., 2004) and Ag-targeting to FcRII even
accelerates Ag-presentation (Yada et al., 2003). In contrast,
an abundance of in vitro data demonstrate that FcRII does
indeed negatively regulate B cell activation (Ashman et al., 1996;
Bijsterbosch and Klaus, 1985; Choquet et al., 1993; Minskoff
et al., 1998; Muta et al., 1994; Nakamura and Cambier, 1998;
Wagle et al., 1999). However, other in vitro data show that the
B cell isoform of FcRII is able to mediate capture and pre-
sentation of some Ag–Ab complexes and might play a role in
BCR-independent Ag-presentation in vivo (Antoniou and Watts,
2002). These latter results are in line with our observation that
in FcRI/III-deficient mice, proliferation of OVA-specific CD8+
T cells was not altered compared to wild-type mice, indicating
that also FcRII can mediate the uptake and presentation of IC.
It has been shown that resting DC induce peripheral tolerance
of CD8+ T cells, whereas activated DC induce priming (Probst et
al., 2003; Probst et al., 2005). As we analyzed CD8+ T cell prolif-
eration only 3 days after IC injection, our results do not conclude
that Ag-presentation mediated by FcRII induces an effector T
cell response. Earlier publications showed that targeting of anti-
gen to the DC receptor DEC-205 in the steady state induced solid
peripheral CD8+ T cell tolerance (Bonifaz et al., 2002). Here,
targeting of DEC-205: Ag to DC in the steady state initially
induced four to seven cycles of T cell proliferation, but the T cells
- Chapter 4 -nly one or two of the FcR does not alter the IC-induced T
ell proliferation. These contrasting findings could be related to
he fact that we analyzed the contribution of the different FcR
n vivo, allowing participation of all APC- and DC-populations.
hereas the studies performed in vitro/ex vivo analyzed the con-
ribution of the FcR on selected populations of DC that might
ot represent all DC-subsets present in vivo.
Recently, a novel murine FcR is described: FcRIV
Mechetina et al., 2002; Nimmerjahn et al., 2005). Our observa-
ions exclude a role for FcRIV in IC-mediated Ag-presentation
nder the conditions used. CD8+ T cell proliferation was
trongly reduced in the FcRIV expressing FcRI/II/III−/− mice
nd T cell proliferation was unaltered in the -chain deficient
ice which do not express FcRIV (and FcRI and FcRIII).
The FcR-dependent cross-presentation is thought to be a
nique property of DC as these cells, but not macrophages and
cells, possess a specialized cross-presentation transport sys-
em for MHC class I Ag-presentation (den Haan et al., 2000;
ung et al., 2002; Regnault et al., 1999; Rodriguez et al., 1999;
chuurhuis et al., 2002). Previous publications have shown that
he enhanced cross-presentation of IC in vivo is depended on
he gamma-chain-containing activating FcR only in a subset
f DC (the CD8−) (den Haan and Bevan, 2002). The CD8+ DC
re shown to present IC also in the absence of the three activating
eceptors (FcR−/−). This is in line with our results, as probably
lso FcRII is involved in uptake and presentation of IC-derived
ntigens. FcRII is thought to inhibit cellular responses to IC
hen it is cross-linked to the activating FcR (Ravetch and
lynes, 1998). However, to date, there are no reports demon-
trating that FcRII negatively regulates Ag-presentation via
ctivating FcR. Recent studies argue against an inhibitorywere then deleted and the mice became specifically unrespon-
sive to rechallenge with Ag. Other studies showed that FcRII
blockade leads to maturation of human monocyte-derived DC
and to increased Ag-specific T cell immunity, suggesting that
the balance between activating and inhibitory FcR is impor-
tant in modifying the immunity to IC (Dhodapkar et al., 2005).
Therefore, it might be possible that cross-linking of the FcRII
receptor does not properly activate the DC, which finally results
in a tolerogenic immune response. In contrast, cross-linking only
the activating FcR might results in a robust effector CD8+ T
cell response. Our results provide a rationale to further study
this possibility as they indicate that FcRII is able to mediate
Ag-presentation after injection of IC, and thus could have the
ability to silence CTL-reactions through the direct capture and
presentation of immune-complexed Ag.
Acknowledgements
This work was supported by a grant from the Netherlands
Organization for Scientific Research (901-07249).
Drs. R.E.M. Toes and A. Ioan-Facsinay are supported by a
VIDI and VENI grant respectively, from The Netherlands Orga-
nization for Scientific Research.
We thank the department of nephrology of the LUMC for the
C3 ELISA and Ohran Demirbacak for excellent animal care.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.molimm.2006.01.002.
51
References
Amigorena, S., Bonnerot, C., 1999. Fc receptor signaling and trafficking: a
connection for antigen processing. Immunol. Rev. 172, 279–284.
Antoniou, A.N., Watts, C., 2002. Antibody modulation of antigen presen-
tation: positive and negative effects on presentation of the tetanus toxin
antigen via the murine B cell isoform of FcgammaRII. Eur. J. Immunol.
32, 530–540.
Ashman, R.F., Peckham, D., Stunz, L.L., 1996. Fc receptor off-signal in the
B cell involves apoptosis. J. Immunol. 157, 5–11.
Barnes, N., Gavin, A.L., Tan, P.S., Mottram, P., Koentgen, F., Hogarth, P.M.,
2002. FcgammaRI-deficient mice show multiple alterations to inflamma-
tory and immune responses. Immunity 16, 379–389.
Bijsterbosch, M.K., Klaus, G.G., 1985. Crosslinking of surface immunoglob-
ulin and Fc receptors on B lymphocytes inhibits stimulation of inositol
phospholipid breakdown via the antigen receptors. J. Exp. Med. 162,
1825–1836.
Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C., Stein-
man, R.M., 2002. Efficient targeting of protein antigen to the dendritic
cell receptor DEC-205 in the steady state leads to antigen presentation on
major histocompatibility complex class I products and peripheral CD8(+)
T cell tolerance. J. Exp. Med. 196, 1627–1638.
Choquet, D., Partiseti, M., Amigorena, S., Bonnerot, C., Fridman, W.H.,
Korn, H., 1993. Cross-linking of IgG receptors inhibits membrane
immunoglobulin-stimulated calcium influx in B lymphocytes. J. Cell Biol.
121, 355–363.
den Haan, J.M., Bevan, M.J., 2002. Constitutive versus activation-dependent
cross- presentation of immune complexes by CD8(+) and CD8(−) den-
dritic cells in vivo. J. Exp. Med. 196, 817–827.
den Haan, J.M., Lehar, S.M., Bevan, M.J., 2000. CD8(+) but not CD8(−)







Jung, S., Unutmaz, D., Wong, P., Sano, G., De los, S.K., Sparwasser, T., Wu,
S., Vuthoori, S., Ko, K., Zavala, F., Pamer, E.G., Littman, D.R., Lang,
R.A., 2002. in vivo depletion of CD11c(+) dendritic cells abrogates prim-
ing of CD8(+) T cells by exogenous cell-associated antigens. Immunity
17, 211–220.
Lanzavecchia, A., 1996. Mechanisms of antigen uptake for presentation. Curr.
Opin. Immunol. 8, 348–354.
Manca, F., Fenoglio, D., Li, P.G., Kunkl, A., Celada, F., 1991. Effect of
antigen/antibody ratio on macrophage uptake, processing, and presentation
to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med.
173, 37–48.
Mechetina, L.V., Najakshin, A.M., Alabyev, B.Y., Chikaev, N.A., Taranin,
A.V., 2002. Identification of CD 16-2, a novel mouse receptor homologous
to CD16/Fc gamma RIII. Immunogenetics 54, 463–468.
Minskoff, S.A., Matter, K., Mellman, I., 1998. Fc gamma RII-B1 regulates
the presentation of B cell receptor-bound antigens. J. Immunol. 161,
2079–2083.
Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M.C.,
Ravetch, J.V., 1994. A 13-amino-acid motif in the cytoplasmic domain of
Fc gamma RIIB modulates B-cell receptor signalling. Nature 369, 340.
Nakamura, K., Cambier, J.C., 1998. B cell antigen receptor (BCR)-mediated
formation of a SHP-2-pp120 complex and its inhibition by Fc gamma
RIIB1-BCR coligation. J. Immunol. 161, 684–691.
Nimmerjahn, F., Bruhns, P., Horiuchi, K., Ravetch, J.V., 2005. FcgammaRIV:
a novel FcR with distinct IgG subclass specificity. Immunity 23, 41–51.
Probst, H.C., Lagnel, J., Kollias, G., van den, B.M., 2003. Inducible trans-
genic mice reveal resting dendritic cells as potent inducers of CD8+ T
cell tolerance. Immunity 18, 713–720.
Probst, H.C., McCoy, K., Okazaki, T., Honjo, T., van den, B.M., 2005. Rest-
ing dendritic cells induce peripheral CD8+ T cell tolerance through PD-1









- Chapter 4 -1685–1696.
hodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E.,
Koenig, S., Steinman, R.M., Ravetch, J.V., Dhodapkar, M.V., 2005. Selec-
tive blockade of inhibitory Fcgamma receptor enables human dendritic
cell maturation with IL-12p70 production and immunity to antibody-
coated tumor cells. Proc. Natl. Acad. Sci. U.S.A. 102, 2910–2915.
etahun, A., Dahlstrom, J., Wernersson, S., Heyman, B., 2004. IgG2a-
mediated enhancement of antibody and T cell responses and its rela-
tion to inhibitory and activating Fc gamma receptors. J. Immunol. 172,
5269–5276.
amano, Y., Arase, H., Saisho, H., Saito, T., 2000. Immune complex and
Fc receptor-mediated augmentation of antigen presentation for in vivo Th
cell responses. J. Immunol. 164, 6113–6119.
azenbos, W.L., Gessner, J.E., Hofhuis, F.M., Kuipers, H., Meyer, D., Hei-
jnen, I.A., Schmidt, R.E., Sandor, M., Capel, P.J., Daeron, M., van de
Winkel, J.G., Verbeek, J.S., 1996. Impaired IgG-dependent anaphylaxis
and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity
5, 181–188.
eath, W.R., Carbone, F.R., 2001. Cross-presentation in viral immunity and
self-tolerance. Nat. Rev. Immunol. 1, 126–134.
oan-Facsinay, A., de Kimpe, S.J., Hellwig, S.M., van Lent, P.L., Hofhuis,
F.M., van Ojik, H.H., Sedlik, C., da Silveira, S.A., Gerber, J., de Jong,
Y.F., Roozendaal, R., Aarden, L.A., van den Berg, W.B., Saito, T., Mosser,
D., Amigorena, S., Izui, S., van Ommen, G.J., van Vugt, M., van de
Winkel, J.G., Verbeek, J.S., 2002. FcgammaRI (CD64) contributes sub-
stantially to severity of arthritis, hypersensitivity responses, and protection
from bacterial infection. Immunity 16, 391–402.
52avetch, J.V., Bolland, S., 2001. IgG Fc receptors. Annu. Rev. Immunol. 19,
275–290.
avetch, J.V., Clynes, R.A., 1998. Divergent roles for Fc receptors and com-
plement in vivo. Annu. Rev. Immunol. 16, 421–432.
avetch, J.V., Kinet, J.P., 1991. Fc receptors. Annu. Rev. Immunol. 9,
457–492.
egnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno,
M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P.,
Amigorena, S., 1999. Fcgamma receptor-mediated induction of dendritic
cell maturation and major histocompatibility complex class I-restricted
antigen presentation after immune complex internalization. J. Exp. Med.
189, 371–380.
odriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P.,
Amigorena, S., 1999. Selective transport of internalized antigens to the
cytosol for MHC class I presentation in dendritic cells. Nat. Cell. Biol.
1, 362–368.
chuurhuis, D.H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J.J., Sedlik,
C., Melief, C.J., Verbeek, J.S., Ossendorp, F., 2002. Antigen–antibody
immune complexes empower dendritic cells to efficiently prime specific
CD8+ CTL responses in vivo. J. Immunol. 168, 2240–2246.
agle, N.M., Faassen, A.E., Kim, J.H., Pierce, S.K., 1999. Regulation of
B cell receptor-mediated MHC class II antigen processing by Fcgam-
maRIIB1. J. Immunol. 162, 2732–2740.
ada, A., Ebihara, S., Matsumura, K., Endo, S., Maeda, T., Nakamura, A.,
Akiyama, K., Aiba, S., Takai, T., 2003. Accelerated antigen presentation







Single Nucleotide Polymorphisms (SNPs) in the C5 
gene associate with susceptibility to RA. 
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Rheumatoid arthritis (RA) is the most common inflammatory arthritis and is a major cause of 
disability. Early theories on the pathogenesis of RA focused on autoantibodies and immune 
complexes. T cell-mediated antigen-specific responses, T cell-independent cytokine 
networks, and aggressive tumor-like behaviour of rheumatoid synovium have also been 
implicated. More recently, the contribution of autoantibodies has returned to the forefront. 
The complement network was initially implicated in human RA, indirectly, by the co-
localization of C3 fragments with immune complexes in joint tissue, and by the 
demonstration that complement activity, as well as early-acting components (C2, C4), is 
routinely depressed in synovial fluid of patients. More recently, more direct evidence for 
complement activation in arthritic joints has been reported. Mice deficient for C5 are resistant 
to serum induced arthritis and anti-C5 monoclonal antibody treatment prevents arthritis in 
mice. Therefore, it is tempting to speculate that the complement system also plays an 
important role in disease pathogenesis in human. 
Here we show that genetic polymorphisms located in the C5 gene locus associate with RA, as 
a common haplotype consisting of 3 SNPs located at positions rs25681, rs17611 and 
rs2416808 is significantly overrepresented in the RA-population. These data indicate that this 
haplotype in the C5 region confers susceptibility to RA. 




The complement system plays an important role in the immune system, providing a highly 
effective means for the destruction of invading micro-organisms and for immune complex 
elimination1,2.  Three pathways of complement activation have been described, the classical 
pathway, the alternative pathway and the lectin (i.e. mannan-binding lectin and ficolins) 
pathway. All lead to cleavage of C3, into C3a and C3b. Binding of C3b enables a better 
clearance of pathogens and immune complexes as well as the generation of the lytic 
membrane attack complex, C5b-9. C5, the fifth component of the complement system is a 
190.000 Mr glycoprotein consisting of 1666 aa in two disulfide-linked polypeptide chains, 
C5α and C5β. When activated by the C5 convertases, C5 is cleaved into C5a and C5b. C5a is 
the most potent complement-derived proinflammatory peptide3. It serves not only as a 
chemoattractant but also initiates multiple defence mechanisms in leukocytes. Through its 
multiple binding sites, C5b initiates and directs the assembly of the membrane attack 
complex. 
C5 is encoded by a single gene copy on chromosome 9q34.1 which contains 41 exons that 
span a genomic region of 79 kb. The gene encodes the open reading frame for C5α (exon 1-
16), as well as for C5β (exons 16-41). Both are transcribed as a single 6.0 kb mRNA and 
translated into a pre-C5 protein (in a β-α orientation). These single chain precursors are 
processed into the mature form of C5 by the removal of the four internal residues to yield a 
two-chain protein4. 
Through activation and interaction with respective receptors on various cells, complement is 
closely linked to the adaptive immune response. A proper functioning complement system is 
also required for physiological tissue regeneration and repair. Complement defects increase 
the susceptibility to infection and are frequently associated with autoimmune disorders5 such 
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as, for example rheumatoid arthritis (RA). RA is a chronic inflammatory disease that attacks 
peripheral joints, leading to their erosion and destabilisation. Although the causes for RA are 
still elusive, it is generally accepted that autoimmune reactions towards joints are of critical 
importance. 
K/BxN T cell receptor transgenic mice are a model of inflammatory arthritis, similar to 
rheumatoid arthritis. In this arthritis model, both T and B cells are required for disease 
initiation, but arthritogenic immunoglobulins (Igs) alone can induce arthritis in lymphocyte-
deficient recipients. These observations indicate that these antibodies are primarily driving 
the disease. Subsequently, it was shown that Fc receptors as well as the complement network 
are crucial to disease induction and progression6. Likewise, mice lacking FcRγ were not 
susceptible to arthritis induction upon injection of collagen or adjuvant7,8; and lack of the 
inhibitory receptor FcγRIIB was found to exacerbate collagen-induced arthritis (CIA) in 
susceptible mouse strains7 or permit its induction in normally resistant stains9. 
Whether FcγR are also involved in RA is not known, but FcγRIII is detected on synovial 
intima in normal and arthritic human joints and on invading macrophages in the latter10. 
Moreover, an FcγRIII gene polymorphism has been correlated with human RA 
susceptibility11 indicating that also in humans FcR are involved in disease pathogenesis. 
That the complement network plays a role in human RA was for the first time detected, 
indirectly, by the colocalization of C3 fragments with immune complexes in joint tissue12, 
and by the demonstration that complement activity, as well as early-acting components (C2, 
C4), is routinely depressed in synovial fluid of patients13. More recently, more direct 
evidence of complement activation in arthritic joints has been reported14. In murine models of 
RA, especially CIA, C5 deficiency has frequently been correlated with disease resistance15, 
although this has not always been the case16. Thus, there is evidence implicating both FcRs 
and the complement network in the aetiology of RA. 
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As mice deficient for C5 are unsusceptible to K/BxN serum induced arthritis17 and anti-C5 
monoclonal antibody treatment prevents arthritis in mice6, we wished to address the question 
whether C5 would also be implicated in RA by determining whether certain genetic variance 
in the C5 locus is associated with RA. 
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Materials and Methods 
 
Patients 
The distribution of C5 alleles was determined in 289 consecutive RA patients who attended 
the out-patient clinic of the Leiden University Hospital in 199418. 
A standard diagnostic evaluation was performed at the first visit. This consisted of a patient 
history, physical and laboratory examinations, and radiographs of the hands and feet19. 
Baseline laboratory examination included an enzyme-linked immunosorbent assay (ELISA) 
for IgM-RF as previously described20 and an anti-CCP-2 antibody ELISA (Immunoscan RA 
Mark 2; Euro-Diagnostica, Arnhem, The Netherlands) which was performed according to the 
manufactures instructions (sensitivity 74%, specificity 97-99%). Patients included in this 
study all had a definite diagnosis of RA according to the American College of Rheumatology 
(formerly, the American Rheumatism Association) 1987 revised criteria21 1 year after 
inclusion in the study. 
 
SNP typing 
Single Nucleotide Polymorphism (SNP) typing in the C5 gene were performed by 
polymerase chain reaction using specific primers (information on the primer sequence and 
thermal cycling conditions will be provided on request) and by PCR-restriction fragment 
length polymorphism analysis. rs25681 and rs17611 were genotyped using time-of-light mass 
spectrometry based Sequenom Mass Array Platform (Sequenom, San Diego, CA, USA). 
 
Quality Control 
Data for each SNP were reviewed independently to verify their quality. We considered each 
SNP to be validated and correctly genotyped for all individuals only if the genotype data met 
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a series of strict criteria including minimum signal intensity specifications and unambiguous 
genotype reading.  Replication of the genotyping of 10% of the samples for each SNP was 
performed randomly and no inconsistencies were detected. 
 
Statistical analysis 
All analysis was performed using SPSS and Statcalc (Centers for Disease Control and 
Prevention, Atlanta, GA). Haplotype frequencies were inferred using Haploview22.  P values 








Polymorphisms in the complement factor 5 gene 
The human C5 molecule lies on the long arm of chromosome 9, at loci 9q34.1. It contains 
97938 bases, running from position 120794170 up to position 120892108, according to the 
NCBI database, and codes for 1676 amino acids. The gene consists of 41 exons, containing 
79 kb. A large number of SNPs are present in the gene, comprising the introns, the exons and 
the untranslated regions (UTR’s) that span the gene. Many SNPs of the C5 gene are already 
registered in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP). 3 SNPs spanning the 




rs25681 rs17611 rs2416808 
 
figure 1: the position of the three genotyped SNPs (rs25681, rs17611 and rs2416808) on the C5 gene. 
 
- Chapter 5 -
61
Table 1: Characteristics of 289 of patients with arthritis of the Leiden University 
Hospital 
Characteristic Value 
Age at onset (mean – SD)   49.9 (14.0)  
Female  61% 
Rheumatoid factor positive   89% 
SE positive   73% 
DRB1.04 positive 22% 
Erosions of hand and feet 90% 
Mean disease duration (years) 13.5 (9.9) 
  
 
Association of SNPs with rheumatoid arthritis 
289 RA patients and 250 controls were genotyped for all 3 SNPs (Table 1). There was no 
significant deviation from Hardy-Weinberg equilibrium in the cases or in the controls (Table 
2). 
A Chi-square trend test was first performed to determine whether there was any difference in 
genotype distribution between cases and controls, followed by an allelic and recessive model 
analysis.  
 
Table 2: Case control analysis of C5 
Alleles               Cases                  Controls Allele Frequency              OR                P
SNP 1/2 11 12 22 Total 11 12 22 Total Cases Controls Allele 11 vs 12+22 Allele 11 vs 12+22
rs2416808 G/A 59 122 62 243 33 127 79 239 0.494 0.404 1.44 2.00 0.0049 0.0034
rs17611 G/A 90 117 44 251 71 125 51 247 0.592 0.540 1.23 1.39 0.1034 0.089
rs25681 C/T 90 117 44 251 72 124 51 247 0.592 0.543 1.22 1.36 0.1177 0.11  
 
SNP rs2416808 (G) is significantly associated with RA whereas SNPs rs17611 (G) and 
rs256181 (C) show a trend. The alleles are overrepresented in the RA population and point 
towards a recessive effect as seen in the significance level (p<0.05) for the recessive model 
analysis. 
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Linkage disequilibrium (LD) analysis reveals that the three SNPs are linked (table 3) with 
SNPs rs17611 and rs25681 being in complete LD (D’=1, R2=0.99) 
 
Table 3: Linkage disequilibrium analysis 
      Pairwise LD
SNP1 SNP2 D' R2
rs2416808 rs17611 0.734 0.35
rs2416808 rs25681 0.733 0.347
rs17611 rs25681 1.000 0.996  
 
Since the level of LD is relative high (as shown by figure 2) it indicates that the effect seen 
might be attributed to a haplotype effect. 
 
   
figure 2: Linkage disequilibrium level. 
 
Haplotype effect 
To investigate this hypothesis, haplotype frequencies were inferred for cases and controls. 
The 3 SNPs (rs25681, rs17611 and rs2416808) were used to determine the haplotype 
frequencies. As seen from Table 4, haplotype GGC is the most frequent in the population. 
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The region shows a high level of linkage disequilibrium explaining the prevalence of only 4 
haplotypes out of the 23 possible haplotypes.  The cut off value for reliable haplotype 
frequency estimation was 2%.  The 4 major haplotypes account for 99-100 % of the total 
population. Haplotype GGC is significantly overrepresented in the RA population (OR=1.26 
P=0.0028), indicating that haplotype GGC confers susceptibility to RA. 
 
Table 4: haplotype structure and frequency in C5 
Haplotypes Frequency Case/Control Frequency ChiSq P
GGC 0.401 0.446, 0.354 8.964 0.0028
AAT 0.383 0.362, 0.405 2.054 0.1518
AGC 0.163 0.144, 0.184 3.043 0.0811





26:500, 28:478  
 




Previously, it has been shown that mice deficient for C5 are resistant to K/BxN serum 
induced arthritis17. Moreover, anti-C5 monoclonal antibody treatment prevents arthritis in 
mice6, indicating that C5 is crucially involved in the process that contributes to arthritis. In 
this study, we investigated the contribution of the C5 gene in human rheumatoid arthritis. 
We show that in the human C5 locus, SNPs rs25681 (C), rs17611 (G) and rs2416808 (G) are 
significantly associated with the susceptibility of RA. The alleles are overrepresented in the 
RA population and point towards a dominant effect. The association appeared to be a 
haplotype effect. Using the 3 SNPs (rs 25681, rs17611 and rs2416808), haplotype CGG is the 
most frequent in the population, and it is significantly overrepresented in the RA population. 
However, to verify these findings replication in other RA populations is required. Likewise, a 
more extensive analysis should be performed by incorporating more SNPs that are also 
localized outside the C5 gene in order to determine whether these associations are, indeed, 
contributed by C5 or are a consequence of genes that are located in the vicinity of the C5 
gene. Moreover, such an analysis will be of importance to identify the causal SNP that is 
underlying the observed associations. 
In conclusion, we provided evidence for association of a particular haplotype of the C5 gene 
with development of RA. Further studies should elucidate the precise nature of this 
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Summary and discussion 

Summary and Discussion 
 
This chapter summarizes this thesis and discusses the main findings of all previous chapters. 
 
Summary 
Chapter 1 starts with a basic introduction into the regulation of the immune system. It 
explains the different functions of CD4+ and CD8+ T cells and how they are activated. CD4+ 
T cells recognize peptide from exogenous antigens presented by MHC class II molecules on 
Antigen Presenting Cells (APC), while CD8+ T cells seem to be restricted to endogenously 
synthesized antigens presented by MHC class I molecules. However, some APC present also 
exogenous antigen on MHC class I, a process called cross-presentation. 
Different APC have been reported to cross-present, including DC, B cells and 
macrophages1,2,3. These different APC are also described in Chapter 1. Furthermore, the 
different types of antigens that are cross-presented are described. Most important are the 
immune complexes, which are shown to be much more efficiently cross-presented than 
soluble antigen4. IC can be taken up by the cell via different receptors. In this thesis the 
FcγReceptors and the complement receptors are discussed. Chapter 1 describes both systems 
extensively. 
Both the FcγR and the complement system are thought to have an important role in the 
development of the autoimmune disease rheumatoid arthritis5. Therefore, this autoimmune 
disease is also shortly introduced in chapter 1. 
 
Dendritic cells (DC) are known for their ability to take up and process IC via FcγR, and they 
have been shown to play a crucial role in IC-processing onto MHC class I as they contain a 
specialized cross-presenting transport system required for MHC class I Ag-processing6,7. The 
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MHC class II-Ag-processing pathway is distinct. Therefore various other professional APC, 
like macrophages and B cells, all displaying FcγR, are thought to present IC-delivered Ag in 
MHC class II. 
In chapter 2 the contribution of these APC in IC-facilitated Ag-presentation is analyzed. We 
showed that, in mice, both macrophages and DC, but not B cells, efficiently capture IC. 
However, only DC, but not macrophages, efficiently activate Ag-specific MHC class II 
restricted CD4+ T cells. These results indicate that mainly DC and not other professional 
APC, despite expressing FcγR and MHC class II, contribute significantly to IC-facilitated T 
cell activation in vivo under steady-state conditions. 
 
Fcγ Receptors and the complement system are mainly responsible for the uptake of IC by 
dendritic cells in vitro. To study the role of the different FcγR and complement in Ag 
presentation in MHC class I in vivo we used in chapter 3 mice deficient for FcγRs and or 
complement factors. These mice were injected with CFSE-labelled ovalbumin-specific CD8+ 
T cells followed by administration of OVA-anti OVA IgG complexes intravenously. 
Surprisingly, the Ag-presentation was marginally affected in FcγRI/II/III-deficient as well as 
in FcR γ-chain-deficient mice. Central complement factor C3-deficient mice and 
FcγRI/II/IIIxC3-deficient mice displayed a similar capacity to present IC as wild-type mice. 
In contrast, strongly reduced CD8+ T cell proliferation was found in mice deficient for C1q. 
This proliferation could be restored when the IC were incubated with purified human C1q 
before injection. Likewise, purified C1q could strongly enhance the presentation of IC by DC 
in vitro. These results indicate a novel function of complement factor C1q in the uptake of 
intravenously administrated IC and presentation of IC to MHC class I to CD8+ T cells by 
APC. 
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Subcutaneously injected IC are preferably taken up via FcγR without the apparent 
involvement of the complement system. To study the contribution of the different FcγR and 
complement receptors in presentation of subcutaneously administrated IC, we analyzed in 
chapter 4 the ovalbumin(OVA)-specific CD8+ T cell proliferation in FcγR- and complement 
component 3 (C3)-deficient mice after subcutaneous injection of OVA-IC. Here we showed 
that the efficient Ag-presentation was FcγR-, but not C3-mediated, as it was inhibited in 
FcγRI/II/III-deficient mice but unaffected in C3-depleted mice. However, no difference was 
found between wild-type and FcγRI/III-deficient or wild-type and FcγRII-deficient mice. 
These results indicate that Ag-presentation via the activating FcγR is not enhanced in the 
absence of FcγRII, and point to redundancy of the FcγR, including FcγRII, in the uptake and 
presentation of s.c. injected soluble IC to CD8+ T cells. 
 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and is a major cause of 
disability. Early theories on the pathogenesis of human RA focused on auto-antibodies and 
immune complexes. T cell-mediated antigen-specific responses, T cell-independent cytokine 
networks, and aggressive tumour-like behaviour of rheumatoid synovium have also been 
implicated. More recently, more direct evidence for complement activation in arthritic joints 
has been reported and therefore, the contribution of auto-antibodies has returned to the 
forefront8. 
Furthermore, mice deficient for C5 are resistant to serum induced arthritis and anti-C5 
monoclonal antibody treatment prevents arthritis in mice9. Therefore, it is tempting to 
speculate that the complement system also plays an important role in disease pathogenesis in 
human. 
In chapter 5 we showed that genetic polymorphisms located in the C5 gene locus associate 
with RA, as a common haplotype consisting of 3 SNPs located at positions rs25681, rs17611 
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and rs2416808 is significantly overrepresented in the RA-population. These data indicate that 
this haplotype in the C5 region confers susceptibility to RA. Further studies are necessary to 
analyse the precise nature of this association of C5 with susceptibility to RA. 
 
Discussion 
Our results in chapter 2 indicate that the ability to present IC-derived Ag in the context of 
MHC class II molecules for the activation of CD4+ T cells is a characteristic that is 
predominantly confined to DC. This does not exclude the fact that macrophages and B cells 
do play an important role in various autoimmune diseases. However, concerning our results it 
is more likely that the IC-related contribution of these APC is associated to release of pro-
inflammatory cytokines and molecules after FcγR-cross-linking, the inefficient clearance of 
IC, or the destruction of autoantibody opsonized cells The ability to organize the T cell 
response is, most likely, the responsibility of the DC. 
 
In contrast to in vitro studies, we show in chapter 4 that in vivo FcγR (including the inhibitory 
FcγRII) are redundant, as deficiency in only one or two of the FcγR does not alter the IC-
induced T cell proliferation. These contrasting findings could be related to the fact that we 
analyzed the contribution of the different FcγR in vivo, allowing participation of all APC- and 
DC-populations. Whereas the studies performed in vitro/ex vivo analyzed the contribution of 
the FcγR on selected populations of DC that might not represent all DC-subsets present in 
vivo. 
Furthermore, it has been shown that resting DC induce peripheral tolerance of CD8+ T cells, 
whereas activated DC lead to CD8+ T cell priming10. As we analyzed CD8+ T cell 
proliferation only 3 days after IC injection, our results do not conclude that Ag-presentation 
mediated by FcγRII induces an effector T cell response. It might be possible that cross-linking 
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of the FcγRII does not properly activate the DC, which could finally result in a tolerogenic 
immune response. In contrast, cross-linking only the activating FcγR might results in a robust 
effector CD8+ T cell response11. Our results provide a rationale to further study this possibility 
as they indicate that FcγRII is able to mediate Ag-presentation after injection of IC, and thus 
could have the ability to silence CTL-reactions through the direct capture and presentation of 
immune-complexed Ag. 
 
Overall, our results show that both FcγR and complement factors play an important role in IC-
facilitated antigen-presentation, depending of the route by which the IC is administrated. 
In contrast to subcutaneous injected IC (chapter 4), the efficient presentation of intravenously 
administrated IC (chapter 3) does not crucially depend on FcγR. When IC are intravenously 
injected the complement factor C1q showed to play an important role in IC-derived Ag-
presentation, inducing a link between innate and adaptive immune responses. This novel 
function of C1q may be of relevance for the design of improved vaccination strategies against 
infectious diseases, auto-immune diseases and cancer. 
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Ons immuunsysteem beschermt ons tegen allerlei ziekteverwekkers, zoals bacteriën, 
parasieten en virussen, die ons lichaam binnen dringen. Een dergelijke ziekteverwekker wordt 
ook wel een pathogeen genoemd. Het immuunsysteem kan worden opgedeeld in een 
“aangeboren” en een “verworven” deel. Het verworven systeem kan zich aanpassen aan het 
pathogeen. Dit kost tijd, maar dit geeft uiteindelijk wel een sterke afweer. Bovendien is ons 
lichaam daarna vaak langdurig beschermd tegen deze pathogenen. Het aangeboren, ofwel 
aspecifieke systeem is daarentegen direct werkzaam en vormt daarmee een belangrijke, brede, 
eerstelijns verdediging tegen vele pathogenen. Maar, doordat dit aangeboren systeem minder 
specifiek is, is de afweer soms minder optimaal. 
Beide afweersystemen bevatten zowel humorale als cellulaire componenten. Humorale 
componenten zijn enzymen die zich in vloeistoffen in het lichaam bevinden, bijvoorbeeld in 
het bloed. Deze enzymen remmen zelf het pathogeen of activeren andere enzymen of cellen 
die het pathogeen opruimen. Een humorale component van het aangeboren immuunsysteem is 
het complementsysteem. Het complementsysteem bestaat uit een groep eiwitten die na 
activatie een cascade (kettingreactie) vormen, wat uiteindelijk kan leiden tot het aantrekken en 
activeren van cellen van het immuunsysteem en schade aan het pathogeen. 
Cellulaire componenten zijn cellen die werken voor het immuunsysteem, zoals de witte 
bloedcellen. De witte bloedcellen zijn cellen van het immuunsysteem die zich in het bloed of 
in de lymfevloeistof bevinden en omvat cellen zowel uit het aangeboren als uit het verworven 
immuunsysteem. Macrofagen (fagocyten) en T- en B-cellen (lymfocyten) zijn vrij bekende 
witte bloedcellen. Macrofagen fagocyteren (Opnemen van het pathogeen in de cel door 
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blaasjes in het celmembraan te maken en zo het pathogeen te omgeven) de ziekteverwekker 
en breken ze af in zogenoemde lysosomen. 
Elke cel of molecuul heeft specifieke structuren op het oppervlak (epitopen). B-cellen 
ontwikkelen antistoffen specifiek voor epitopen op het vreemde materiaal. Elk antistof is 
specifiek voor een antigen, zo'n vreemde structuur. Antilichamen bestaan namelijk uit een 
variabel en een constant deel. Het variabele deel bepaalt de specificiteit van het antilichaam. 
Het constante deel bepaalt op welke wijze het antilichaam een immuunreactie op gang brengt. 
Op basis van dit constante deel kunnen de antistoffen in 5 typen verdeeld worden. Namelijk: 
IgD, IgM, IgA, IgG en IgE. Wanneer een antilichaam is gebonden aan zijn antigen wordt het 
vreemde materiaal nog makkelijker als vreemd beschouwd en opgeruimd door fagocyten, 
bovendien hindert de binding van antilichamen het functioneren van het pathogeen. 
T-cellen hebben op hun oppervlak specifieke receptoren die een bepaald stukje van een 
pathogeen (een peptide) herkennen. Deze peptiden worden gepresenteerd door speciale 
moleculen op het oppervlak van het pathogeen, namelijk het Major Histocompatibility 
Complex (MHC). Er zijn twee typen MHC, MHC klasse I en MHC klasse II, die elk herkend 
worden door een ander soort T-cellen. 
Cytotoxische T-cellen (ook wel CD8+ T-cellen genoemd, omdat ze het molecuul CD8 op hun 
oppervlak hebben) herkennen peptiden die gepresenteerd worden in MHC klasse I. MHC 
klasse I komt op alle cellen voor en presenteert alleen peptiden die in de cel zelf voorkomen. 
Echter een cel die door een virus is geïnfecteerd zal ook virale peptiden in MHC klasse I 
presenteren. CD8+ T-cellen herkennen zo welke cellen geïnfecteerd zijn met virus en zullen 
deze cellen opruimen. 
Helper T cellen (ook wel CD4+ T-cellen genoemd) herkennen peptiden die gepresenteerd 
worden in MHC klasse II. MHC klasse II komt alleen voor op speciale cellen in het 
afweersysteem, namelijk de Antigeen Presenterende Cellen (APC). Deze APC nemen een 
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pathogeen op met behulp van een bepaald opname systeem; knippen het pathogeen in stukjes 
en presenteren die peptiden in het MHC klasse II molecuul. 
Sommige APC kunnen, via een bepaald systeem, het peptide van het opgenomen pathogeen 
ook presenteren in MHC klasse I. Dit systeem heet “crosspresentatie”. Door dit systeem zijn 
deze cellen in staat een zeer sterke T-cel reactie op te wekken. Maar het mechanisme 
waarmee crosspresentatie plaats vindt is nog niet helemaal duidelijk. 
Er zijn verschillende soorten cellen die kunnen functioneren als APC. Namelijk dendritische 
cellen, B-cellen en macrofagen. De dendritische cellen staan het meest bekend om hun 
mogelijkheid tot crosspresentatie. Maar er zijn ook artikelen verschenen waarin beschreven 
wordt dat B-cellen en macrofagen dit kunnen doen. 
 
Immuuncomplexen 
Er zijn verschillende soorten antigenen beschreven die door middel van crosspresentatie in 
MHC klasse I gepresenteerd worden. Hieronder vallen ook de immuuncomplexen (IC). IC 
zijn antigenen gebonden aan antilichamen. Uit verschillende onderzoeken is gebleken dat IC 
veel gemakkelijker “cross gepresenteerd” worden dan antigenen alleen. Verder vormen ze een 
belangrijke factor bij een snelle tweede immuunreactie tegen een intracellulaire pathogeen 
waartegen B-cellen al eens eerder antistoffen gemaakt hebben. 
IC komen ook vaak voor in ontstekingsgebieden bij bepaalde auto-immuunziekten. Het zou 




Immuuncomplexen worden door een APC opgenomen met behulp van een bepaald soort 
receptoren, de FcReceptoren. Er zijn verschillende soorten FcReceptoren. Eén hiervan is de 
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FcγReceptor, welke specifiek is voor IC waarin IgG antilichamen participeren. Binding van 
een IC via het IgG aan deze FcγReceptoren resulteert uiteindelijk in de activatie van een T-cel 
die het pathogeen opruimt. FcγReceptoren vormen dus een belangrijke link tussen het 
aangeboren en verworven immuunsysteem. 
De FcγReceptoren kunnen weer onderverdeeld worden in drie klassen: FcγRI, FcγRII en 
FcγRIII. In muizen is onlangs zelfs een vierde klasse ontdekt, namelijk FcγRIV. FcγRI, III en 
IV worden activerende receptoren genoemd. Omdat binding van een IC aan een van deze 
receptoren leidt tot activatie van een immuunreactie. FcγRII is echter een remmende receptor. 
 
Het complement systeem 
Het complement systeem speelt een belangrijke rol in het immuunsysteem; het zorgt voor de 
afbraak van een binnengedrongen pathogeen en voor verwijdering van immuuncomplexen. 
Het complement systeem is een onderdeel van het aangeboren immuunsysteem, maar is ook 
betrokken bij de activatie van het verworven immuunsysteem. 
De cascade van reacties van het complement systeem wordt gecontroleerd door een groot 
aantal eiwitten. Er zijn 3 routes van complement activatie beschreven: de klassieke route, de 
alternatieve route en de lectin route (zie figuur 3 in hoofdstuk 1). 
Alle 3 de routes leiden tot de activatie van complement factor C5. Activatie van C5 en 
binding van complement componenten C6, C7, C8 en meerdere C9 moleculen, resulteert 
uiteindelijk tot de vorming van het “membrane attack complex”. Dit complex maakt een 
gaatje in de celwand van een pathogeen of geïnfecteerde cel, waardoor de cel kapot gaat. 
Verder zorgt de vorming van factor C5a er voor dat er nog meer hulptroepen naar het 
geïnfecteerde gebied getrokken worden, wat de ontstekingsreactie verder in gang zet. 
Immuuncomplexen activeren het complement systeem via de klassieke route, door binding 
van complement factor C1q. Verschillende cellen van het immuunsysteem hebben ook 
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specifieke complement receptoren op hun oppervlak. Door binding van complement factoren 
aan antigenen, zoals immuuncomplexen, kunnen deze antigenen via de complement 
receptoren door de cellen opgenomen en afgebroken worden. 
 
Auto-immuunziekten 
Onder normale omstandigheden beschermt het immuunsysteem ons tegen binnendringende 
ziekteverwekkers. Helaas werkt dit systeem niet zonder fouten en vind er soms activatie van 
het systeem plaats wanneer dat niet nodig is en veroorzaakt het schade. Zo vindt er in auto-
immuunziekten een immuunreactie plaats tegen lichaamseigen moleculen. Vooral fouten in 
een van de eerste componenten van de klassieke route van het complement systeem (C1q, 
C1r/C1s, C4 en C2) zorgen vaak voor auto-immuniteit in de mens. Er wordt gedacht dat 
verstoring van deze route leidt tot het verkeerd opruimen van immuuncomplexen. 
Reumatoïde artritis (reuma) is een van de meest voorkomende auto-immuunziekten. Er wordt 
gedacht dat antilichamen gericht tegen lichaamseigen stoffen een belangrijke rol spelen in 
deze ziekte. Onlangs is er een muizenmodel ontdekt waarin muizen spontaan reuma kregen. 
Antilichamen en immuuncomplexen bleken hierin een belangrijke rol te spelen. De reuma kon 
zelfs overgebracht worden naar andere muizen, door bloed van een zieke muis in te spuiten in 
een gezonde muis. De muizen kregen echter geen reuma als ze geen FcγReceptoren of 
complement factor C5 in hun lichaam hadden. Deze factoren lijken dus een belangrijke rol te 
spelen in de ontwikkeling van reuma. 
 
Dit proefschrift 
In dit proefschrift is een studie gedaan naar de rol van de verschillende FcγReceptoren en het 
complement systeem in de immuunreacties veroorzaakt door immuuncomplexen. Hiervoor 
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zijn verschillende muismodellen gebruikt die vaak 1 of meerdere FcγReceptoren of 
complement factoren miste. 
Allereerst hebben we in hoofdstuk 2 gekeken naar de rol van de verschillende Antigeen 
Presenterende Cellen in de presentatie van peptiden in MHC klasse II aan CD4+ T cellen. 
Dendritische cellen (DC) worden beschouwd als de belangrijkste APC in de activatie van T-
cel reacties, omdat ze vele receptoren (waaronder FcγReceptoren) voor opname van antigenen 
op hun oppervlak hebben. Maar ook andere APC, zoals B-cellen en macrofagen, hebben 
FcγReceptoren én MHC klasse II op hun oppervlak. Wij laten zien dat, in muizen, zowel 
macrofagen als DC goed in staat zijn IC op te nemen. Echter, alleen de DC zijn in staat een 
efficiënte antigeenspecifieke MHC klasse II gereguleerde CD4+ T-cel reactie te activeren. 
In hoofdstuk 3 hebben we gekeken naar de rol van FcγReceptoren en het complement 
systeem in de presentatie van IC aan CD8+ T-cellen door IC in de bloedbaan te spuiten van 
verschillende muizen, die bepaalde FcγReceptoren of complement factoren misten. Het bleek 
dat er een veel slechtere CD8+ T-cel reactie was in muizen die geen C1q hebben. Deze T-cel 
reactie kon worden hersteld als de muizen ingespoten werden met C1q of als we eerst C1q 
lieten binden aan de IC voordat we het IC in de muis spoten. Dit duidt op een geheel nieuwe 
functie van C1q. 
Vervolgens hebben we in hoofdstuk 4 wederom gekeken naar de rol van FcγReceptoren en 
het complement systeem in de presentatie van IC aan CD8+ T-cellen. Maar dit keer hebben 
we de IC niet in de bloedbaan van de muizen gespoten, maar onderhuids. Hier bleken de 
FcγReceptoren een belangrijke rol te spelen, omdat muizen die geen enkele FcγReceptor 
hadden, een veel minder goede T-cel reactie vertoonden. Echter, deze rol kon niet specifiek 
toegewezen worden aan een van de vier typen FcγReceptoren. 
Tenslotte, hebben we in hoofdstuk 5 nog een studie gedaan in de mens. Omdat muizen die 
geen complement factor C5 hebben ongevoelig zijn voor reuma, vroegen we ons af of de 
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menselijke vorm van reuma ook beïnvloed wordt door C5. Hiervoor hebben we het C5 gen in 
gezonde mensen vergeleken met het C5 gen in mensen met reuma. Het bleek dat een kleine 
genetische verandering in het C5 gen vaker voorkomt in mensen met reuma dan in gezonde 
mensen. Dit duidt erop dat deze kleine genetische verandering gepaard gaat met de 
gevoeligheid voor het ontwikkelen van reuma. 
 
Samengevat, kunnen we zeggen dat zowel FcγReceptoren als het complement systeem een 
belangrijke rol spelen in de presentatie van antigen afkomstig van immuuncomplexen. Het 
hangt echter wel af van de route waarop het IC toegediend wordt. In tegenstelling tot 
onderhuids geïnjecteerde IC, hangt de presentatie van in de bloedbaan geïnjecteerde IC niet af 
van FcγReceptoren. Hier blijkt namelijk C1q een grote rol te spelen. Hiermee vormt C1q een 
belangrijke link tussen het aangeboren en verworven immuunsysteem. Deze “nieuwe” functie 
van C1q zou wel eens van belang kunnen zijn voor het ontwikkelen of verbeteren van 
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